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Abstract 
 Myocardial infarction is a prominent medical problem in the world today. Current treatments are 
limited and do not strive to regenerate the myocardial tissue that is lost post-infarction. Human 
mesenchymal stem cells (hMSCs) have been shown to improve cardiac function when implanted post-
infarction. The effectiveness of stem cell therapy largely depends on the delivery method. Current 
delivery methods are insufficient due to their low cell engraftment rate and inability to target the 
endocardium, where most myocardial infarctions occur. Biological microthreads are a promising new 
local cell delivery method that may improve upon these current limitations. We hypothesize that 
biological microthreads will increase efficiency of hMSC delivery to the beating rat heart compared to 
intramyocardial injection. To test our hypothesis we seeded biological microthreads in vitro with 100 μL 
of cell suspension (100,000 hMSCs). After one day, an average of 11,806 ± 3,932 hMSCs were counted 
on the biological microthreads. The biological microthreads were attached to suture needles to allow 
targeted delivery to the rat heart (in the left ventricular wall). Human mesenchymal stem cells were 
loaded with quantum dots prior to seeding the biological microthread bundles or delivery to the rat heart 
via injection. For intramyocardial injection, a cell suspension containing 10,000 hMSCs (35 μL) was 
injected into the myocardial wall using a 100 μL syringe. The delivery efficiency of each method was 
determined by sectioning the heart into 8 µm thick sections and analyzing three sections every sixty 
sections (24 µm every 480 µm) for quantum dot loaded hMSCs. These sections were stained with 
Hoechst dye and quantum dot loaded cells in the heart sections were manually counted. The delivery 
efficiency of each biological microthread implantation was calculated by dividing the number of counted 
quantum dot loaded hMSCs in the heart wall by the average number of hMSCs on the biological 
microthread bundles (normalized to the length that was implanted in the heart wall) after 24 hours. The 
delivery efficiency of intramyocardial injection was calculated by dividing the number of counted 
quantum dot loaded hMSCs in the heart wall by 10,000 (the number of cells injected). Biological 
microthread mediated hMSC delivery had a significantly higher delivery efficiency (66.6 ± 11.1%) 
compared to intramyocardial injection (11.8 ± 6.25%) after 1 hour (p < 0.05). Biological microthread 
implantation tracking illustrated that we were able to deliver hMSCs to the myocardium and endocardium 
of the left ventricular wall for hMSC delivery. This study illustrates that biological microthreads can serve 
as an efficient means of delivering hMSCs to the infarcted heart. Unlike the currently utilized delivery 
methods, biological microthreads can target the infarcted layer of the left ventricular wall and maximize 
hMSC engraftment to that layer.   
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Chapter 1: Introduction 
 The heart provides the body with essential nutrients and allows for the exchange of oxygen and 
carbon dioxide. Without this pump, the organs and tissue that make up the body would not function. 
Since the heart is of such an utmost importance, any decrease in its function would alter the function of 
the entire body. Myocardial infarction is the death of heart muscle that is generally caused by the 
blockage of a blood vessel (coronary artery) that supplies a region of the heart with blood. Scar tissue 
forms post-infarction over the dead tissue where the cardiac myocytes perished. This scar tissue is a very 
hostile environment for cells due to its decreased blood flow and acidic pH. Scar tissue is also non-
contractile, which reduces the overall cardiac output of the heart [1].  
 A majority of cardiac myocytes do not proliferate. At the age of 25 about 1% of myocytes 
proliferate annually, and 0.45% at the age of 75 [2]. It has been reported that this number increases to a 
maximum of 4% after a myocardial infarction [3]. However, clinically the heart is unable to regenerate 
itself [4]. The scar tissue that forms post-infarction has different mechanical properties than the healthy 
myocardial tissue. Over time, this weakened part of the heart can begin to swell and form a ventricular 
aneurysm [5]. The current treatment methods for ventricular aneurysms include direct linear closure and 
endocardial patch plasty. Both methods require the removal of the infarcted tissue, however direct linear 
closure sutures the heart closed while endocardial patch plasty uses a patch to replace the excised tissue 
[6]. Endocardial patch plasty as well as direct linear closure aim to transform the heart from the spherical 
shape it forms post-infarction back into the healthy elliptical shape it is naturally. Both of these methods 
focus on restoring the shape of the heart. However, they do not restore the tissue that was lost during the 
infarction, which contributed to the overall function of the heart before the infarction occurred.  
 Cardiac regeneration is possible with cellular therapy. Human mesenchymal stem cells (hMSCs) 
have been utilized to improve cardiac function by increasing vascularity as well as limiting scarring in the 
infarction zone [7],[8]. One of the major problems with cardiac cellular therapy is associated with the cell 
delivery method. Current delivery methods are inefficient, with cell engraftment rates ranging from 1-
25% depending on the method [9],[10]. The efficiency of a delivery method is defined as the number of 
cells that engraft in the heart wall divided by the number of cells that were initially delivered. Another 
issue with the current delivery methods is the inability to deliver cells directly to the endocardium, the 
innermost layer of the ventricular wall where most infarctions occur. Biomaterials are being researched to 
improve localization and efficiency of cell delivery. These biomaterials, which include fibrin, gelatin, and 
collagen, are being formed into three-dimensional scaffolds as well as gels that can be implanted directly 
on or in the ventricular wall to allow for local delivery [10-12]. These biomaterial delivery methods do 
have a higher engraftment rate than other non-localized delivery methods, but also have limitations. Cell 
retention is the main problem in gels, while nutrient delivery to seeded cells is the main problem in three-
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dimensional scaffolds [11],[13]. These problems need to be overcome in order to consistently deliver cells 
to the heart post-infarction. Our main objective is to overcome these limitations by developing a delivery 
method using a new scaffold that will allow efficient, targeted delivery of cells to the ventricular wall. 
 Fibrin microthreads, which were first developed by Cornwell et al., are a novel form of fibrin that 
are shaped like suture and have significantly higher tensile strength than other forms of fibrin including 
fibrin gels and glue [14]. Fibrin is found naturally at the site of wound healing where it serves as a matrix 
for the attachment and migration of cells. Fibrin gels have been used to deliver cells to the infarcted 
myocardium in several studies [11, 15]. Cornwell et al. utilized the fibrin microthreads as scaffolds for 
tissue regeneration. Specifically, the fibrin microthreads were shown to allow fibroblast attachment, 
proliferation, and alignment [14]. Fibrin microthreads have also been proven to support human 
mesenchymal cell (hMSC) growth and viability by Murphy et al. [16] Implantation of fibrin microthreads 
is possible since we are able to connect fibrin microthreads to suture needles. Several designs, which 
allowed the connection of the fibrin microthreads to suture needles, were developed to ensure consistent 
fibrin microthread delivery. With a proper design, we are able to implant the fibrin microthreads in vivo. 
 Self-assembled collagen microthreads were developed as scaffolds for tissue regeneration. Other 
forms of collagen have been used to deliver cells to the infarcted myocardium [17, 18]. Human 
mesenchymal stem cells attach at a higher rate to fibrin microthreads than self-assembled collagen 
microthreads. However, in terms of mechanical properties, self-assembled collagen microthreads have 
nearly double the tensile strength of fibrin microthreads (9.05 MPa vs. 4.78 MPa) [19]. A scaffold that 
has both the superior cell seeding properties of fibrin microthreads and the high mechanical strength of 
collagen microthreads would be ideal for in vivo implantation. “Hybrid” microthread bundles were 
developed based on the concept of combining fibrin microthreads with collagen microthreads to create a 
scaffold with sufficient mechanical properties and cell seeding ability.  
 Intramyocardial injection surgery involves the injection of a bolus of cells directly into the 
myocardium. Other than knowing how deep the syringe needle has gone, the most apparent shortcoming 
of this cell delivery method is low cell engraftment since the cells easily reach the blood circulation and 
engraft in other organs such as the lungs. A large percentage of the cells are also pushed out of the heart 
wall due to the outward pressure that the heart applies when it contracts [4].   
 We hypothesize that biological microthreads will increase the efficiency of hMSC delivery to the 
beating rat heart compared to intramyocardial injection. The biological microthreads can be implanted 
into the ventricular wall, in close proximity to the endocardium. The biological microthreads will improve 
upon efficiency because the surgeon can implant the biological microthread bundle into the heart wall, 
close to the infarction area and therefore increase the chances of the hMSCs seeded on the biological 
microthreads engrafting in the infarction area.  
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Chapter 2: Background 
 The main objective of this project is to improve upon the current myocardial cell delivery 
methods by developing a novel approach for stem cell delivery to the infarcted myocardium. Since a 
novel approach is being developed, the underlying aspects that support and define the method must be 
explored. Previous work has been done by this lab that proves that biological microthreads are capable of 
serving as a scaffold for human mesenchymal stem cell (hMSC) delivery [16]. This background section 
will illustrate the fundamentals of cardiac anatomy and myocardial infarction as well as explore the 
current methods of cardiac cell delivery.  
2.1: Healthy Myocardial Function and the Infarcted Myocardium 
The heart is the main pump of the circulatory system that delivers nutrient-rich blood to the body.  
The heart is composed of four chambers, the left ventricle being the chamber where the highest pressures 
are reached. The wall thickness of each chamber depends on the maximum pressure reached during 
normal function. The innermost layer of the heart wall is known as the endocardium; the outermost layer 
is known as the epicardium [20]. Myocardial muscle cells (myocytes) are electrically connected with gap 
junctions that allow the propagation of action potentials to occur. The propagation of the action potential 
causes rhythmic contraction of the myocytes. When the heart contracts blood is pumped out of the 
ventricle and into the aorta and coronary arteries, supplying blood to the entire body [21, 22].  
 The myocardium has a coronary circulation which provides oxygen and nutrients to the 
myocytes. If any portion of the coronary circulation is blocked, a population of the myocytes may be 
starved. Initially, when the coronary circulation is occluded, the production of adenosine triphosphate in 
the heart is changed from a natural aerobic mechanism to a compromised anaerobic mechanism. The 
reason for this change is simply an insufficient supply of glucose and oxygen to the tissue. The result of 
this change is a dramatic decrease in the production of adenosine triphosphate. Myocytes require 
adenosine triphosphate to function and this dramatic decrease results in an inability of the muscle to 
contract. The energy reserve for adenosine triphosphate production, creatine phosphate, is then depleted 
shortly thereafter. The intracellular pH of the myocytes decreases as anaerobic glycolysis persists because 
of the buildup of hydrogen ion byproduct [23].  Osmosis causes water to enter the myocytes and as the 
heart tissue swells, cell death occurs due to edema. After several weeks or even months, scar tissue forms 
over the damaged tissue because of the infiltration of collagen depositing fibroblasts into the infarction. 
Further migration of monocytes, neutrophils, and macrophages to the infarction zone occurs due to the 
inflammatory response. Matrix metalloproteinases (MMPs) that are released from the neutrophils cause 
myocyte collagen degradation and infarction expansion [1].  
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 The leading cause of death in the United States is cardiovascular disease [24]. Nine hundred 
twenty thousand people in the United States annually suffer from myocardial infarction. Myocardial 
infarction and coronary heart disease cost patients in the United States over $156 billion a year [25]. After 
a myocardial infarction occurs, 22% of men and 46% of women are diagnosed with heart failure within 
six years. At this point, the heart is unable to pump a sufficient amount of blood to the body’s organs, 
significantly altering a patient’s ability to perform even basic physical tasks.   
2.1.1: The Rat Heart 
 The rat heart has a similar coronary circulation as a healthy human heart (Figure 1). Blood first 
enters the heart from the right atrium via the vena cava, passes through the tricuspid valve into the right 
ventricle, passes through the pulmonary valve into the pulmonary artery. The blood then travels through 
the lungs and is oxygenated, returns to the left atrium from the pulmonary vein, passes through the mitral 
valve into the left ventricle, and finally exits the heart by passing through the aortic valve into the aorta 
which delivers oxygenated blood to the body [26]. The key difference between the rat and human heart, 
other than size, is heart rate. The average rat heart beats at a rate of 400 beats per minute, while a healthy 
human heart beats at a rate of 70 beats per minute [27]. Despite this difference, the physiological 
similarities between the human and rat heart are the reason that the rat was chosen as a suitable model for 
assessing cardiac stem cell therapy. Future studies will also focus on delivering hMSCs in a rat 
myocardial infarction model and assessing cardiac function post-delivery. The rat heart can be infarcted 
by coronary artery ligation and utilized to study the effects of hMSC therapy on heart function [28, 29].       
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Figure 1: Rat heart blood circulation pathway [26] 
2.2: Current Treatments for Myocardial Infarction 
 After a myocardial infarction, the heart cannot repair itself. Post-infarction scar tissue forms over 
the dead tissue where the cardiac myocytes perished. If the infarction is not treated, the scar tissue will 
begin to thin and the dimensions of the left ventricle start to change [30]. Myocardial infarction also has 
profound effects on the general function of the heart. Ejection fraction, the amount of blood in the 
ventricle that is ejected with each stroke of the heart, decreases depending on the size of the infarction. 
The normal stroke volume, the amount of blood ejected from the ventricle with each heart beat, is initially 
maintained despite the decrease in ejection fraction because of compensatory responses. The 
compensatory responses increase the stress in the ventricular wall because of the extra pressure and 
volume applied. The increase in stress can cause complications including aneurysms and rupture [30]. 
 The current treatments for myocardial infarction only strive to treat the effects of infarction by 
performing bypass surgery or restoring the normal shape of the heart from a spherical shape to the natural, 
more efficient elliptical shape. A typical procedure that restores blood flow is coronary artery bypass 
grafting, or CABG. However, CABG does not actually treat the infarct [31]. Surgical ventricular 
restoration is a more recent procedure that is gaining popularity as clinical trials demonstrate its 
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effectiveness [32]. There are two possible procedures for ventricular restoration, endocardial patch plasty 
and direct linear closure [6].  
 Direct linear closure requires the surgeon to remove the infarcted myocardium and suture the 
heart tissue back together. The main goal of this surgery is to restructure the size and shape of the heart. 
Since a portion of the myocardium is being removed, the closure is not always perfect, resulting in less 
than optimal dimensions. If the infarction size exceeds a certain size, endocaridal patch plasty is 
performed instead of direct linear closure. Endocardial patch plasty requires a patch to be sutured in place 
of the infarcted tissue [33]. The specific procedure is known as the Dor procedure and requires the heart 
to be completely arrested. Coronary revascularization is required to allow blood flow to reach the 
epicardial layer of the heart wall and maintain the infarct thickness [31]. The infarction is then excised 
and a balloon is inflated in the left ventricle to guide the restoration of the heart. A suture is utilized to 
tighten the ventricle to the shape of the balloon. Once this step is completed, a biomaterial patch of 
polytetrafluoroethylene (PTFE) or polyethylene terephthalate (PET) is used to replace the excised tissue 
and close the remaining gap in the heart wall. The purpose of the patch is to prevent further changes in the 
shape and volume of the ventricle [33, 34].  
 The surgical techniques in this section focus on restoring the ventricular dimensions and 
pressures. None of them aim to regenerate the cells that are lost when a myocardial infarction occurs. 
There are several issues with the materials which are used for endocardial patch plasty that can affect the 
life of the patient. These materials have been shown to form large regions of fibrosis and are nearly four 
orders of magnitude stronger than the heart muscle, causing a large discrepancy in the mechanical 
properties. Despite all of the surgical effort required for these procedures, the overall function of the heart 
remains compromised because the infarcted tissue does not contribute.  
2.3: Myocardial Cellular Therapy 
Cardiac regeneration has become the focus of cardiac cellular therapy. Instead of excising the 
infarcted tissue, cellular therapy aims to restore the tissue back to its functional form. A variety of cell 
types, including bone marrow stem cells, skeletal myoblasts, embryonic stem cells, and cardiac stem cells 
have been employed for myocardial cellular therapy [35-38]. Embryonic stem cells are controversial and 
currently increase the risk of tumor formation. Skeletal myoblasts do not have the ability to electrically 
couple with cardiac myocytes. There is still no agreement in the scientific community about the existence 
of cardiac stems cells. Sufficient quantities of fetal cardiomyocytes cannot be obtained for effective 
clinical use [39-41]. Based on all of these factors, human mesenchymal stem cells (hMSCs) were chosen 
to pursue cardiac regeneration.   
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 Human mesenchymal stem cells only represent 0.001% to 0.01% of the total nucleated cells in 
the bone marrow, where they are acquired [42]. They are able to differentiate into several different tissue 
types including fat, cartilage, and bone. They also are adherent and multipotent cells. In terms of tissue 
regeneration, these cells are ideal due to their relatively high proliferation rate, genetic stability, and ease 
of isolation [40, 42, 43]. For cardiac regeneration, hMSCs have been shown to induce angiogenesis, 
differentiate into a cardiac myocyte-like phenotype after being delivered to the heart, and are capable of 
being utilized allogeneically without causing an immune response [41, 42, 44]. 
 Researchers have delivered hMSCs to the heart and discovered many improvements in cardiac 
function post-delivery. Improvements include an increase in ventricular performance and a decrease in 
infarction size [13, 35, 45-48]. Researchers have also shown the potential these cells may have to 
differentiate into myocytes and possibly release cytokines or growth factors, which could encourage the 
natural repair of the heart [13, 35, 48]. In 2009, Hare et al. completed clinical trials in which allogeneic 
hMSCs were delivered intravenously to humans. The trials were double-blind, placebo-controlled, dose-
escalating, and multi-center. Fifty three patients were enrolled for the 6-month trial period from 10 
different study centers. The trial concluded that hMSCs did not increase toxicity when compared to 
placebo, the hMSC treated group had four times fewer arrhythmia events, and the hMSC group had a 
significant increase in left ventricular ejection fraction [49]. 
 Even though hMSCs have demonstrated their positive potential when delivered to the heart, the 
exact mechanism that is responsible for these improvements is not completely understood. There are 
several theories currently: differentiation of delivered hMSCs, cell fusion, a presence of passive cells in 
the myocardial wall, and paracrine signaling [50]. Despite the controversy surrounding the mechanism by 
which hMSCs improve cardiac function, researchers agree that hMSCs restore a portion of cardiac 
function. For this reason, hMSCs will be the cells delivered to the heart for this project.  
2.3.1: Current Drawbacks of Cellular Therapy 
As shown in this section, cellular therapy has a great deal of potential. However, there are 
limitations that hinder the extent of the positive impact that these cells are capable of. A majority of the 
limitations are due to the delivery method and include insufficient localization, cell retention, cell 
survival, and a lack of a matrix for cell attachment that can result in cell death [4, 39, 41, 51].  
Intramyocardial injection requires the injection of a certain volume of cell suspension directly 
into a myocardial infarction. The limitation of this delivery method is that once the syringe needle is 
removed, the cells are pushed out due to the contraction of the heart [4]. The main problem with systemic 
delivery is the lack of localization. When cells are delivered systemically, a majority of the cells engraft 
in organs other than the heart including the liver, lungs, and spleen [47, 52]. For this delivery method the 
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cells are suspended in either media or phosphate buffered saline (PBS). After injection, there is low cell 
attachment and a high rate of cell death. These limitations strongly affect the myocardial engraftment rate, 
which ranges from 1 to 10% [4, 40]. 
 Hou et al. injected peripheral blood mononuclear cells (PBMNCs) intramyocardially and 
determined delivery efficiency in the ischemic swine heart. It was determined that the delivery efficiency 
was 11 ± 3% and when compared to intracoronary (IC) and interstitial retrograde coronary venous (IRV) 
delivery, intramyocardial injection (IM) had the highest delivery variability and efficiency. It was also 
found that 43 ± 3% (IRV), 26 ± 3% (IM), and 47 ± 1% (IC) of the cells were found in the lungs for each 
of the respective delivery methods. These numbers are startlingly large and with certain cell types may 
cause unwanted consequences [53]. 
Since the engraftment rates of current hMSC delivery methods are so low, the number of cells 
delivered must be optimized to overcome these limitations. Researchers currently deliver between 
500,000 to 50,000,000 cells to each animal subject [35, 44, 47, 52, 54]. Table 1 illustrates typical cardiac 
cell delivery numbers to rodent models with various scaffold types. The number of cells that engraft can 
be calculated using the percent engraftment reported by the researcher. 
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Type of cell Animal Model Cell Count Scaffold Reference 
Bone marrow-
derived 
mononuclear cells 
Rat 8 x 10
6 
cells/cm
2 
PGCL polymer [55] 
Bone marrow MSCs Rat 1 × 10
5
 cells/cm
2
 Bovine pericardium [56] 
Bone marrow MSCs Mouse 1 x 10
6 
cells/cm
2 
Collagen matrix [57] 
Bone marrow MSCs Rat 2.2 × 10
6
 cells/cm
2
 
Type I collagen-
GAG scaffold 
[58] 
Bone marrow cells Rat 1 x 10
7 
cells/cm
2 
PGAC cloth [59] 
Bone marrow MSCs Rat 1 × 10
6
 cells/cm
2
 PLCL scaffold [60] 
Bone marrow MSCs Rat 5 × 10
4
 cells/cm
2 
Acellular bovine 
pericardium 
[12] 
 
Table 1: Scaffolds used for MSC delivery in rodent models and MSC seeding counts 
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2.4: Cardiac Regeneration with Biomaterials 
The limitations of myocardial cellular therapy are largely due to inefficiency of the current 
cellular delivery methods including cellular cardiomyoplasty and systemic delivery. Biomaterials aim to 
improve cell delivery by allowing the control of the cellular microenvironment, which in turn allows 
researchers to command cell behavior [61]. When using biomaterials for the creation of a scaffold, several 
scaffold properties must be considered including degradation rate, porosity, cell adhesion, size, and 
compliance [10, 39, 61]. Numerous scaffold designs have been created for use in cardiac applications 
using gelatin, fibrin, collagen, and alginates in the form of gels or 3D scaffolds [9-12, 15, 62-66]. 
Alginate is a natural polysaccharide that is derived from brown seaweed. Alginate is used in gel 
and 3D sponge form for cell delivery to the infarcted heart [67]. Leor et al. was able to create a cardiac 
graft using a cell seeded alginate sponge. Other researchers have had similar success with alginate due to 
its hydrophilic nature, biocompatibility, neovascularization in vivo, and adjustable porosity [10, 67-69]. 
The drawback of alginate is its inability to interact with mammalian cells because of a lack of arginine-
glycine-aspartic acid (RGD) ligands that allow cell adhesion. To overcome this limitation, alginate is 
often covalently modified with this ligand [67].  
Gelatin sponges are biomaterials composed of purified porcine skin gelatin [70]. Li et al. and 
Akhyari et al. have utilized gelatin sponges for culturing and delivering cells to the heart. Gelatin sponges 
are biodegradable and support cell attachment and cell contraction. Gelatin sponges also have 
shortcomings including, natural thrombogenicity and a high level of porosity which make it unsuitable for 
blood contacting applications [70-72].    
Collagen is the most abundant protein in mammals. It is also known as the primary component of 
connective tissue. Collagen has been used successfully in cardiac applications for cell delivery and 
contraction. Like alginate, collagen comes in many forms; gels or 3D sponges are most common [9, 62, 
73]. Collagen has several properties that demonstrate its potential as a scaffold including cell attachment, 
cell proliferation, high hydrophilicity, and degradability. Veritas™ is an example of a 3D collagen matrix 
that can be utilized to deliver cells to the heart. 
Fibrin is created during the wound healing process and serves as a provisional matrix for cell 
attachment and migration. Thrombin is produced at the site of a wound and fibrinogen naturally circulates 
in the blood. When fibrinogen and thrombin are combined, a fibrin clot is created to halt bleeding and 
assist in healing  [74, 75]. Thrombin and fibrinogen are also available commercially and allow the 
creation of fibrin sealants and glues [37]. Fibrin naturally has RGD binding motifs that allow cell 
adhesion, can potentially be created with autologous thrombin and fibrinogen, is angiogenic, and is FDA 
approved for clinical use [11, 76, 77].  
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Currently, the biggest challenge for injectable gel mediated cell delivery is cell and gel retention. 
However, cell survival is improved with these gels [11, 37, 65]. 3D scaffolds used for infarction 
regeneration, on the other hand, have other shortcomings that include insufficient nutrient diffusion and 
vascularization [11, 13]. Since these 3D scaffolds are usually approximately 2-4 mm thick, nutrients 
cannot diffuse through the entire thickness. Nutrients can only diffuse through a maximum depth of 150 
µm [4]. Since a majority of the scaffold will not contain nutrients, a large quantity of the cells seeded on 
the scaffold will not remain viable when implanted. For this reason, a new type of scaffold must be 
developed to improve cell viability and targeted cell delivery in a myocardial infarction. A new type of 
scaffold should degrade at a rate that allows cell engraftment while not interfering with cardiac function. 
Angiogenesis must also be induced to ensure proper nutrient flow via new blood vessels [61].  
2.4.1: Collagen and Fibrin Microthreads 
Type I collagen microthreads were originally developed to repair ligaments and tendons because 
of the similarities in mechanical properties. Type I collagen microthreads allow for cell attachment and 
proliferation to occur and do not lose strength after 20 days of cell culture. In fact, these collagen 
microthreads exhibited increased strength after being seeded with cells [78-82]. The main purpose of 
using collagen microthreads in the heart is mechanical reinforcement. When the suture needle pulls the 
microthread bundle through the wall of the heart it causes weaker materials to fail, like fibrin 
microthreads. For this reason, collagen microthreads were used.  
Discrete fibrin microthreads, developed by Cornwell et al., are another novel scaffold type which 
was developed for tissue regeneration.  Fibrin microthreads allow cell migration, control cell orientation, 
and provide cell signaling [19]. Fibrin microthreads were first evaluated by Cornwell et al., and were 
determined to have higher tensile strength than fibrin gels. Cornwell et al. also demonstrated that fibrin 
microthreads support fibroblast alignment, growth, viability, and migration after 7 days of cell culture. 
Murphy et al. showed that fibrin microthreads also support human mesenchymal stem cell (hMSC) 
viability and proliferation, and allow the hMSCs to retain their pluripotency [16]. Murphy et al. were also 
able to seed the fibrin microthreads with a physiologically relevant (to the heart) quantity of hMSCs. In 
addition, fibrin microthreads can also be modified by crosslinking to increase tensile strength and loaded 
with growth factors to alter cellular function [14, 19].  
Fibrin and collagen microthreads are promising scaffolds for cell delivery.  Combining these two 
scaffold types into a single bundle increases tensile strength, by using collagen, while maintaining the cell 
seeding properties of fibrin. When bundled together, this hybrid scaffold can be used as an effective, 
localized cell delivery method. Like intramyocardial injection, biological microthread mediated hMSC 
delivery strives to deliver cells directly into the myocardial infarction, and is therefore a localized delivery 
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method. Delivery methods such as intravenous infusion rely on hMSCs homing to the myocardial 
infarction, and are therefore non-localized. Fibrin and collagen are biodegradable. Fibrin can be loaded 
with growth factors and is angiogenic. In terms of structure, fibrin and collagen microthreads are shaped 
like suture, and therefore can be used in a manner similar to suture. When bundled together, fibrin and 
collagen microthreads can be attached to a suture needle and the microthreads can be delivered into the 
heart wall, much closer to the actual infarction when compared to other localized cell delivery methods.    
2.5: Cell Tracking with Quantum Dots 
Since hMSCs are being delivered to the rat heart, cell tracking must be employed to distinguish 
the delivered cells from the cells that already populate the heart. Cells can be labeled with particles in 
order to employ positron emission tomography (PET) or magnetic resonance imaging (MRI). However, 
these methods are relatively expensive due to the equipment they require and can only track greater than 
10,000 cells [83]. Secondary staining (LacZ for example) is also an option, but false positives are too 
commonly generated [84]. In addition, secondary staining is time intensive.  
Fluorescent cell tracking utilizes fluorescent proteins, polymethines, or inorganic/organic hybrids 
to emit light at a specific wavelength when exposed to ultraviolet light [85]. Fluorescent dyes and green 
fluorescent proteins are difficult to distinguish in the heart due to an abundance of autofluorescence [4].  
An important advantage to using fluorescent cell tracking is the ability to track cells with any fluorescent 
microscope. Quantum dots, specifically, are fluorescent nanocrystals that are about 10-20 nm in size [86]. 
Rosen et al. determined that quantum dots enter hMSCs via endocytosis after 24 hours of incubation in 
quantum dot solution [87]. Quantum dot filters, which were used to view quantum dot signal under a 
fluorescent microscope, also elicit minimal heart tissue autofluorescence. Compared to other filters, 
which allow an excessive amount of autofluorescence to pass through, the quantum dot filter ensures that 
loaded cells are easily found.  
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Chapter 3: Hypothesis and Specific Aims  
We hypothesize that biological microthreads will increase the efficiency of hMSC delivery to the 
beating rat heart compared to intramyocardial injection. The rat heart will be sectioned and histologically 
analyzed after the desired implantation time of the biological microthreads. We will implant biological 
microthreads and inject a bolus of hMSCs intramyocardially in different in vivo groups and compare the 
different methods. The biological microthread implantation group will also be analyzed to determine the 
location of the delivered hMSCs.  
 
Specific Aim 1: Compare engraftment of hMSCs in the rat heart (intramyocardial injection vs. 
biological microthreads) 
For this specific aim, we hypothesize that more hMSCs will engraft in the rat heart with 
biological microthread cell delivery versus intramyocardial injection. In order to test this specific aim, we 
bundled 8 fibrin microthreads with 4 collagen microthreads and attached this bundle to a suture needle. 
We first loaded our hMSCs with 655 ITK carboxyl quantum dots for cell tracking. We then seeded the 
biological microthreads with hMSCs and incubated them for 1 day. After incubation, the cell seeded 
microthreads were implanted in the rat heart for one hour. In the intramyocardial injection group, a bolus 
of 10,000 hMSCs was injected into the myocardial wall of the left ventricle. One hour after implantation, 
the rat was euthanized and the heart was removed for histological analysis. The heart was sectioned next 
after being frozen in O.C.T. into 8 µm thick sections. Three sections were histologically analyzed every 
480 µm using Hoesct dye to visualize cell nuclei. Each microscope image was taken with two filters: the 
Hoechst and quantum dot filter. These two images were merged using ImageJ software to confirm that the 
images contained quantum dot loaded hMSCs. The quantum dot loaded cells were then manually counted. 
These counts were used to calculate hMSC delivery efficiency to the rat heart. Delivery efficiency 
illustrated the potential effectiveness of each delivery method.  
 
Specific Aim 2: Determine localization of hMSCs in the rat heart for biological microthread 
delivery 
For this specific aim, we hypothesize that the biological microthreads will uniformly deliver 
hMSCs throughout the length of the implant. We also hypothesize that the biological microthreads will 
deliver cells to the entire thickness of the left ventricular wall. To test this, we first seeded quantum dot 
loaded hMSCs on hybrid bundles of fibrin-collagen microthreads which were attached to suture needles. 
The hMSCs were then incubated on the microthreads for 1 day. After incubation, the cell seeded 
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microthreads were implanted in the rat heart for 1 hour and the rat was euthanized. After euthanization, 
the heart was removed for histological analysis. The rat heart was then sectioned into 8 µm thick sections 
after being frozen in O.C.T. Compound. One section was histologically analyzed every 480 µm using 
Masson’s trichrome staining to determine the location of the biological microthread implantation. Each 
microscope image was taken at 5x magnification and Adobe Photoshop software was used to determine 
the distance of the biological microthread from the endocardium and the epicardium of the left ventricular 
wall in the rat heart. These distances were graphed to illustrate the location of the microthread in the left 
ventricular wall for the entire length of the implantation. The hMSC delivery distribution along the length 
of the microthread bundle was determined using the method described in Specific Aim 1 to determine the 
engraftment rate (three Hoechst dyed heart sections analyzed every 480 µm). 
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Chapter 4: Materials and Methods  
In this section, the protocols used to accomplish our specific aims will be described. Collagen and 
fibrin microthread production and hMSC seeding on these microthreads will be detailed. The surgical 
procedure used to implant the biological microthread bundles as well as how the heart will be sectioned 
and histologically analyzed will also be discussed.  
4.1: Collagen and Fibrin Microthread Production and Seeding 
Collagen microthreads were created using a previously established protocol [88]. Type I collagen 
was first extracted from rat tails using a previously published procedure [89]. The type I collagen was 
then extruded through 0.86 mm diameter polyethylene tubing (Becton Dickinson, Inc., Franklin, NJ), 
using a syringe pump (KD Scientific, New Hope, PA), at a flow rate of 0.7 mL/min. The type I collagen 
threads were extruded into a fiber formation buffer bath (pH 7.42, 135 mM NaCl, 30 mM TrizmaBase 
(Tris), and 5 mM NaPO4 dibasic; Sigma, St. Louis, MO) which was maintained at a temperature of 37⁰C. 
After 24 hours, the microthreads were moved into fiber incubation buffer (pH 7.42, 135 mM NaCl, 10 
mM Tris, and 30 mM sodium phosphate dibasic, Sigma) which was maintained at a temperature of 37⁰C. 
After 24 hours, the microthreads were moved into and kept in distilled water for 24 hours at 37⁰C. Lastly, 
the microthreads were taken out of the water bath, air dried, and stored in a desiccator at room 
temperature before usage (see Figure 3).  
 
  
Figure 2: Fibrin microthread scanning electron micrograph (left) and extrusion diagram (right) [19] 
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Figure 3: Collagen microthread scanning electron micrograph [19] 
 
 Fibrin microthreads were created using a previously established protocol [19]. Two separate 1 mL 
syringes were each filled with thrombin and fibrinogen taken from bovine plasma (Sigma Aldrich, St.  
Louis, MO). A blending application tip was used to combine the thrombin and fibrinogen and the 
combined solution was extruded through 0.38 mm polyethylene tubing (Beckton Dickinson,  Franklin 
Lakes, NJ) into a 10 mM HEPES, 7.4 pH bath that was kept at room temperature (see Figure 2). After 15 
minutes in the bath, the microthreads were taken out and air dried. 
 The mechanical properties of the individual fibrin and collagen microthreads were insufficient to 
be implanted in the rat heart. Fibrin microthreads that were bundled together also lacked the ability to be 
implanted in the rat heart due to insufficient mechanical properties. Individual fibrin and collagen 
microthreads also have very little surface area for cells to attach to. For these reasons, we grouped 
together the collagen and fibrin microthreads into a single microthread bundle. Bundling the microthreads 
was performed by placing eight fibrin and four collagen microthreads adjacent to each other and dragging 
a droplet of distilled water along the length of them until they formed a single bundle (see Figure 4).  
Bundling these microthreads increases total surface area which augments cell seeding capacity, increases 
the probability of successful implantation, and creates grooves in between the individual microthreads to 
improve initial cell attachment. 
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Figure 4: Microthread bundling 
 
 The day before seeding the microthread bundles, the hMSCs were quantum dot loaded for cell 
tracking. The quantum dot media was created by adding Qdot 655 ITK™ carboxyl quantum dots 
(1.025μL qdot solution per 1 mL media, Invitrogen Q2132MP, Carlsbad, CA)  to Mesenchymal Stem 
Cell Growth Medium (MSCGM:  10%  mesenchymal  stem  cell growth  supplement,  2%  L-glutamine,  
0.1%  gentamicin  sulfate/amphotericin-B  in mesenchymal  stem  cell  basal medium, Lonza, 
Walkersville, MD). The next step was to remove the media from the flask of hMSCs and replace it with 
the quantum dot media. The hMSCs were then placed in a 37⁰C, 5% CO2 incubator for 24 hours and then 
rinsed with sterile PBS prior to seeding.  
 In order to seed the microthreads, the microthread bundles were first attached to suture needles then 
placed into a bioreactor that consisted of 1.98 mm I.D. Silastic tubing (Dow Corning, Midland, MI) 
sealed with side clamps (see Figure 5). A 27G needle was used as an inlet port to sterilize and eventually 
seed the microthread bundle. In order to prepare for sterilization, the microthreads were rehydrated by 
adding PBS, via the 27G needle, to the bioreactors for 15 minutes. The PBS was removed and replaced 
with 70% ethyl alcohol, via the 27G needle, for 1 hour. The final step was to rinse the microthreads for 15 
minutes, three times with sterile PBS via the 27G needle.  
 Ten minutes after the removal of the sterile PBS, the biological microthread bundles were seeded 
with hMSCs. Seeding the microthreads involved first trypsinizing human mesenchymal stem cells 
(Lonza, Walkersville, MD) then centrifuging and suspending them at a concentration of 1,000,000 
cells/mL in Mesenchymal Stem Cell Growth Medium (MSCGM:  10%  mesenchymal  stem  cell growth  
supplement,  2%  L-glutamine,  0.1%  gentamicin  sulfate/amphotericin-B  in mesenchymal  stem  cell  
basal medium, Lonza, Walkersville, MD). For all mesenchymal stem cell based experiments, passage 4-9 
cells were used. One hundred microliters of cell suspension was injected into the bioreactor with one side 
clamp removed to allow air to escape. Ten microliters of cell suspension was put on a 4 well chamber 
slide to ensure proper quantum dot loading of the hMSCs. The bioreactors were then put into 50 mL 
conical tubes with holes cut into them to allow oxygen to reach the cells. The conical tubes were then put 
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into a MACSmix™ rotisserie (Miltenyi Biotec, Bergisch Gladbach, Germany, see Figure 6) and the 
rotisserie was placed into a 37⁰C, 5% CO2 incubator for 24 hours while spinning the cells at 4 rpm. This 
allowed the cells to adhere to all sides of the microthread bundle.  After 1 day of culture, the microthread 
bundles were removed from the incubator and implanted in the rat heart.     
 
 
 
Figure 5: Biological microthread seeding diagram 
 
 
Figure 6: Microthreads placed in tube rotator 
Side clamps 
Microthread 
bundle 
25 G syringe 
needle 
Suture needle 
1.98 mm I.D 
Polyethylene 
tubing 
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4.2: Quantifying Cells Seeded on Biological Microthreads 
Quantifying the number of cells on each microthread bundle allowed the calculation of cell 
delivery and seeding efficiency. After seeding the microthreads with hMSCs, one microthread bundle was 
stained with Hoechst (nuclear stain) and Phalloidin (f-actin filament) stain and two others were 
trypsinized in order to count the seeded cells with a hemocytometer. These two methods will be described 
in detail in this section.  
4.2.1: Qualitative analysis of cell seeding using Hoechst dye and Phalloidin stain 
After one day of culture, one microthread bundle was used for qualitatively analyzing cell 
seeding with Hoechst and Phalloidin staining. The microthreads were first removed from the bioreactors 
and suture needles and placed on glass slides. The microthreads were then rinsed with PBS, fixed in 4% 
paraformaldehyde (Boston  Bioproducts, Worcester, MA), and rinsed with PBS twice for 5 minutes. The 
microthreads were then permeabilized with 0.25% Triton X-100 in PBS for 10 minutes, blocked with 1% 
bovine serum albumin in PBS for 10 minutes, and stained with Alexa Fluor 488 conjugated phalloidin 
(5μL stock solution in 200μL PBS, Invitrogen A12379, Carlsbad, CA) for 30 minutes to help discern the 
f-actin filaments in the cytoskeleton. The microthreads were then rinsed three times for 10 minutes with 
1% bovine serum albumin in PBS and counterstained for 5 minutes with Hoechst dye (Cambrex Bio 
Science, Charles City, IO) at a 1:6000 concentration to help distinguish the cell nuclei (see Figure 7 for an 
example).  
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Figure 7: Whole 2 cm length of a biological microthread bundle after 1 day of seeding with hMSCs 
(5x magnification for picture on top left, nine 5x pictures merged together for center picture, Hoechst dyed nuclei 
are blue, Phalloidin stained f-actin filaments are green).  
 
Cell seeding was qualitatively analyzed by locating and imaging the cells on the microthread with 
a fluorescent Leica DM LB2 microscope (see Figure 7). In the next section, counting hMSCs after they 
have been trypsinized off of the biological microthreads will be described. However, on some occasions 
trypsinization was not 100% effective. Any biological microthreads that were not digested after 
trypsinization, usually collagen microthreads, were stained with Hoechst and Phalloidin staining to ensure 
that all cells have detached (see Figure 8).    
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Figure 8: Trypsinized whole biological microthread bundle 
(5x magnification for picture on top right, nine 5x pictures merged together for center picture, Hoechst dyed nuclei 
are blue, Phalloidin stained f-actin filaments are green). This image illustrates that on some occasions, hMSCs were 
still attached to the microthread bundles, usually collagen, after 30 minutes of trypsinization.   
 
4.2.1: Quantification of cell seeding using a hemocytometer 
 Hoechst and phalloidin staining provide an excellent visual representation of cell seeding on 
biological microthreads, but was not utilized to quantify cell seeding due to several key limitations. One 
of the limitations is that the rat DNA, which is on the surface of the collagen microthreads that are used in 
the microthread bundle, emits positive signal when stained with Hoechst dye. Rat DNA is on the surface 
of the collagen microthreads because the type I collagen used to make the microthreads was isolated from 
rat tails. This signal makes it very difficult to locate and count the hMSC nuclei that the Hoechst dye 
stains, resulting in a time consuming process. Finally, all of the cells on the microthread bundles cannot 
be seen because of the three dimensional nature of the large 12 biological microthread bundle size. In 
addition to the limited depth of field, the 2D projection of the 3D microthread bundle limits accuracy. The 
microthread bundles overlap and therefore can potentially cover a large population of cells.   
 Since there are numerous limitations to manually counting cells on microthread bundles, 
including reproducibility, visibility of cells, and autofluorescence, this method was not utilized in this 
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project. Hemocytometers are commonly used to count human mesenchymal stem cells (as well as other 
cell types) in many applications, including passaging and seeding biomaterials. Since hemocytometers are 
well-established for counting cells, it was determined to utilize them to count cells that are trypsinized off 
of biological microthreads. The microthreads were first removed from the bioreactor and rinsed with PBS. 
They were then placed in a 1.7 mL microcentrifuge tube with trypsin (at 37⁰C) for 30 minutes. While in 
trypsin, the microthreads were agitated every 5 minutes to maximize cell detachment.  The trypsin was 
then inactivated with Mesenchymal Stem Cell Growth Medium (Lonza, Walkersville, MD) and the 
microthread bundle in solution was centrifuged at 10,000 rpm in the conical tube for 10 minutes. The 
supernatant was then removed and fresh Mesenchymal Stem Cell Growth Medium (Lonza, Walkersville, 
MD) was added to the cells. The cell suspension was added to Trypan blue solution (Invitrogen, Carlsbad, 
CA) and mixed. The combined Trypan blue/cell suspension was transferred into the hemocytometer and 
the cells were counted.  
4.3: Delivering hMSCs to the Rat Heart 
The delivery of hMSCs to the rodent heart was the main focus of this research. The novel method 
which we introduced, biological microthread implantation, was compared to intramyocardial injection. In 
order to compare these two methods, the delivery efficiency was quantified. Analysis of implantation 
position within the myocardium also helped define the surgical consistency of our microthread bundling 
design and determine whether the implantation procedure was reproducible. The best way to test the 
effectiveness of our microthread bundling design was to implant the microthread bundle into the beating, 
live rat heart. This section will describe the surgical procedure to implant seeded biological microthreads 
and inject a bolus of hMSCs into the rat heart.  
All procedures that were performed on animal subjects were approved and overseen by Worcester 
Polytechnic Institute’s Institutional Animal Care and Use Committee (IACUC). The IACUC protocol 
number was 08-01.  
4.3.1: Biological Microthread Implantation and Intramyocardial injection 
 The surgical procedure to implant biological microthreads was relatively straightforward and was 
intended to be easily reproducible. First, the left lateral region of the rat was shaved, concentrating on the 
rib cage to ensure a clean incision surface. The Sprague-Dawley rat (Charles River Laboratories, 
Wilmington, MA) was then intubated with a 16 gauge catheter. The shaved area was then sterilized with 
three alternating applications of 70% ethanol and betadine. The catheter was then attached to a ventilator 
(Columbus Instruments, Columbus, OH) and the rat was covered with sterile surgical drapes. Isoflurane 
was administered (at 2%, titrated to effect) once the rat was connected to the ventilator via a vaporizer. 
An incision was made above the 5
th
 intercostal space to gain access to the muscle layer. The thoracic 
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cavity was reached by carefully cutting the muscle layer with iris scissors and impeding excessive 
bleeding with a cauterizer. Rib spreaders were used to maintain visibility of the thoracic cavity and ensure 
proper implantation of the microthreads or injection of the hMSCs. A cotton applicator was carefully used 
to move the lungs and gain access to the heart. The stem cell seeded biological microthread bundle was 
then passed through the anterior wall of the left ventricle (from just below the base of the heart to just 
above the apex) with a half-circle tapered size 18 suture needle (Securos Surgical, Fiskdale, MA). The 
biological microthreads were then cut from the suture needle and left implanted. Instead of implanting 
biological microthreads, intramyocardial injection required the injection of a bolus of hMSCs into the left 
ventricle of the rat heart. Thirty-five μL of cell suspension (10,000 hMSCs) was drawn into a 100 μL 
syringe (Hamilton Company, Reno, Nevada) with a 27 gauge syringe needle attached (Becton Dickinson 
and Co., Franklin Lakes, NJ) and then injected into the left ventricular wall of the rat heart. One hour 
later, the rat was euthanized and the heart was removed for histological analysis for both the 
intramyocardial injection and biological microthread implantation groups.  
4.4: Histological Analysis of the Rat Heart Post-Implantation or Injection 
 The rat heart was histologically analyzed in order to determine the results of the surgical 
implantation experiments. The rat hearts utilized for both the intramyocardial injection and biological 
microthread implantation groups underwent the same histological analysis. Once the heart was removed 
from the rat it underwent fixation, sectioning, and staining.  The histological analysis steps are detailed 
below.  
4.4.1: Heart sectioning and preparation 
At the conclusion of the surgical aspect of the experiment (1 hour after implantation) the rat heart 
was removed. Once the rat heart was removed it was cut in half, bisecting the microthread or injection 
site. The heart was rinsed with PBS to remove excess blood and then immediately placed in 4% 
paraformaldehyde for 24 hours to allow for proper fixation. After fixation, the rat heart was then placed in 
30% sucrose for 24 hours. Each half of the rat heart was then placed (cut end of heart facing down) in a 
separate Peel-A-Way® Disposable Embedding Mold (Polysciences Inc., Warrington, PA) and covered 
with O.C.T. Compound (Sakura Finetek USA Inc., Torrance, CA). The two rat heart halves were then 
placed in a freezer and the O.C.T. compound was allowed to harden. Once the O.C.T. compound was 
completely frozen, the block containing half of the heart was placed in a Leica CM3050 cryostat (Leica 
Microsystems, Bannockburn, IL) and 8 μm thick heart sections were cut and placed on VWR® Micro 
Slides (VWR International, West Chester, PA).  These microscope slides were stored in a freezer after 
sectioning in order to preserve the heart sections. A schematic of this process is shown below in Figure 9. 
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Figure 9: Bisecting and sectioning the rat heart 
4.4.2: Heart section staining 
 In order to determine the results of the experiments, the heart sections that were cut had to be 
stained. Staining of the heart sections allowed the calculation of total cell delivery, cell delivery 
efficiency, and localization of cell delivery. The first step was to stain every twenty slides (from one end 
of the microthread implantation to the other) with Masson’s trichrome to establish the location and 
orientation of the implanted microthread bundles. Masson’s trichrome staining was not utilized for the 
intramyocardial injection experiments since only cells were delivered.  Hoechst dye (Invitrogen, 
Carlsbad, CA) was used to stain the next set of heart sections. Specifically, three 8 µm thick sections were 
stained with Hoechst dye and sixty 8 µm thick sections were omitted until the next three 8 µm thick 
sections were stained. This pattern was continued until quantum dot loaded hMSCs were no longer visible 
in the heart sections. The same pattern was also used to stain the heart sections with α-Actinin (Sigma-
Aldrich, St. Louis, MO) and Hoechst counter-stain. α-Actinin staining was utilized to confirm that the 
quantum dot loaded cells were hMSCs and not striated cardiac myocytes.  
In order to stain the heart sections with Masson’s Trichrome, the following steps were performed: 
The heart sections (on microscope slides) were first rinsed with distilled water and then put in Bouin 
solution (Sigma-Aldrich HT10-1-128, St. Louis, MO) for 1 hour at 56⁰C. The heart sections were then 
allowed to cool and washed with running tap water until the yellow color disappeared. The heart sections 
were stained with Weigert hematoxylin (Sigma-Aldrich HT107 and HT109, St. Louis, MO) next for 10 
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minutes. The sections were then washed with warm running tap water for 10 minutes. The sections were 
then stained in Biebrich scarlet-acid fuchsin solution for 5 minutes. The sections were then rinsed in 
distilled water and placed in Phosphomoybdic/Phosphotungstic acid solution for 15 minutes. The sections 
were stained in aniline blue solution next for 3 minutes and rinsed in distilled water. The sections were 
then placed in 1% acetic acid solution for 3 minutes and finally rinsed several times with tap water. An 
example of a Masson’s Trichrome-stained section is shown in Figure 10. 
Staining the heart sections with sarcomeric α-actinin was performed with the following protocol: 
the heart sections were first rinsed with PBS twice for 5 minutes. The heart sections were then 
permeabilized with 0.25% Triton X-100 in PBS for 20 minutes, blocked with 1.5% normal rabbit serum 
in PBS for 30 minutes, and then the monoclonal sarcomeric anti-α-actinin primary antibody was placed 
on the heart sections for 24 hours at 4⁰C in a humidity chamber (1:400 in 1.5% normal rabbit serum, 
Sigma A7811, St. Louis, MO). The heart sections were then rinsed three times for 5 minutes with PBS 
and the Alex Fluor 488 rabbit anti-mouse secondary antibody was applied for 45 minutes (1:400 in 1.5% 
normal rabbit serum, Invitrogen A11059, Carlsbad, CA).  The heart sections were rinsed three times for 5 
minutes with PBS and counterstained for 5 minutes with Hoechst dye (Cambrex Bio Science, Charles 
City, IO) at a 1:6000 concentration. 
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Figure 10: Masson's trichrome stained rat heart section 
(5x magnification, collagen microthreads are blue, fibrin microthreads are red) 
4.4.3: Counting and calculating cells delivered to the heart 
 Staining the heart sections allowed the visualization of the cell nuclei and microthread implant. 
Staining also confirmed that quantum dot loaded hMSCs were being delivered to the heart. However, 
quantum dot loaded cells were manually counted from the Hoechst dyed sections. Examples of quantum 
dot loaded hMSCs can be seen in Figure 11. In the microthread implantation section there are a total of 5 
quantum dot loaded cells, while there are 4 quantum dot loaded cells in the intramyocardial injection 
section (arrows). Figure 11 illustrates some of the challenges that emerge when quantum dot loaded cells 
are in close proximity. When in close proximity, individual quantum dot loaded cells cannot be 
distinguished from each other. To reduce the possibility of double counting quantum dot loaded cells, 
whenever there was a strong signal around several nuclei, the number of quantum dot loaded cells, as 
counted, would be one cell. Properly quantum dot loaded hMSCs have quantum dots in the cytoplasm of 
the cell; therefore quantum dot signal should be in the immediate vicinity of the cell nuclei. Only cell 
nuclei with a 5 µm minimum diameter were counted to reduce the possibility of double counting the same 
cell if it spanned adjacent sections. In many cases, if a slice of a nucleus (with a diameter less than 5 µm) 
was seen in a section, either the previous or subsequent section would contain the full diameter of the 
same nucleus.  Once three consecutive sections were analyzed for quantum dot loaded cells, 60 sections 
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were skipped and another three sections were analyzed. This pattern was continued until quantum dot 
loaded cells were no longer visible in the sections.  
   
  
 
Figure 11: Quantum dot loaded hMSCs delivered to the rat heart  
(40x magnification, Hoechst dyed nuclei are blue, Quantum dots are red). A: quantum dot loaded hMSCs injected 
into rat heart. B: quantum dot loaded hMSCs delivered to the rat heart with biological microthreads. Single 
quantum dot loaded hMSCs are indicated with arrows. The quantum dot loaded hMSC count is conservative 
because if there is more than one nucleus within a “cloud” of quantum dot signal, only a single cell was counted. 
The biological microthread bundle is outlined with a dotted white line.  
   
A 
B 
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Manually counting three sections every sixty sections obviously does not indicate the total 
number of cells delivered to the heart. Manually counting all heart sections, over 400 sections per 
experiment, would have been impractical because of the cost and time that it would require. Each counted 
section (3 sections per slide) was stained with Hoechst dye, coverslipped, and analyzed with a fluorescent 
microscope. Each of these steps was done with care to ensure that all sections were analyzed properly. In 
order to calculate the total number of cells delivered to the heart, some assumptions had to be made. It 
was assumed that there was a linear relationship between each of the slides (three rat heart sections per 
slide, see Figure 12). For example, the total number of cells delivered from slide 1 to slide 21 in EXP0214 
would be calculated as follows: ((6 + 15) / 2) x 20 = 210.  
 
Figure 12: Counting hMSCs delivered to the rat heart  
This graph illustrates how the number of quantum dot- positive hMSCs delivered to the rat heart was calculated. 
These numbers were taken from EXP0214, where the total number of hMSCs delivered to the rat heart was 
determined to be 2670. There are 3 rat heart sections on each slide.   
 
Once the total number of cells delivered to the heart was calculated, the delivery efficiency could 
be determined.  In order to determine the delivery efficiency, the biological microthread implant length 
and depth had to be measured. Equation 1 was used to determine the delivery efficiency of each 
microthread implantation:  
𝑕𝑀𝑆𝐶𝑠 𝑒𝑛𝑔𝑟𝑎𝑓𝑡𝑒𝑑 𝑖𝑛 𝑕𝑒𝑎𝑟𝑡 𝑤𝑎𝑙𝑙
 𝐿𝑒𝑛𝑔𝑡𝑕 𝑜𝑓 𝑖𝑚𝑝𝑙𝑎𝑛𝑡𝑒𝑑 𝑚𝑖𝑐𝑟𝑜𝑡𝑕𝑟𝑒𝑎𝑑
2 𝑐𝑚 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑖𝑐𝑟𝑜𝑡𝑕𝑟𝑒𝑎𝑑 𝑙𝑒𝑛𝑔𝑡𝑕 ∗ 𝑕𝑀𝑆𝐶𝑠 𝑜𝑛 𝑚𝑖𝑐𝑟𝑜𝑡𝑕𝑟𝑒𝑎𝑑 𝑏𝑢𝑛𝑑𝑙𝑒
 
 
Equation 1: Microthread implantation delivery efficiency calculation 
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The implant length was the distance between where the implanted biological microthread entered and 
exited the heart. The implant depth was the maximum distance from the outside of the heart that the 
microthread was implanted (this number was calculated by analyzing trichrome stained histological 
sections of the rat heart). The implant depth was usually not at the center point of the implantation length 
and therefore was the maximum implant depth. Based on this number, the total length of microthread 
implanted inside the heart could be calculated (see  
Figure 13). The delivery efficiency of each intramyocardial injection was calculated using Equation 2: 
 
𝑕𝑀𝑆𝐶𝑠 𝑒𝑛𝑔𝑟𝑎𝑓𝑡𝑒𝑑 𝑖𝑛 𝑕𝑒𝑎𝑟𝑡 𝑤𝑎𝑙𝑙
10,000 𝑕𝑀𝑆𝐶𝑠 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑜 𝑕𝑒𝑎𝑟𝑡 𝑤𝑎𝑙𝑙 
 
 
Equation 2: Intramyocardial injection delivery efficiency calculation 
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Figure 13: Determination of microthread implanted length and depth in the rat heart  
This figure shows how implant length and depth are determined, and how the total implantation length is calculated. 
Once these values are determined in trichrome stained section, the lower image is drawn to make a triangle based 
on these values. The hypotenuse of ½ the implant length and implant depth (the two legs of the right triangle) is 
determined using the Pythagorean Theorem. The hypotenuse value is multiplied by two to represent the combination 
of the two hypotenuses, which is an estimate of the length of microthread implanted in the rat heart.     
 
4.4.4: Tracking microthread implantation in the rat heart 
In order to determine the location of the microthread in the rat heart (left ventricular wall) the 
heart sections were stained with Masson’s trichrome stain as previously described. These stained heart 
sections were imaged (at 5x magnification) with a Leica DM LB2 microscope with a Leica DFC-480 
digital camera attached. Adobe Photoshop software was utilized to determine the distance of the 
biological microthread implant from the innermost section of the endocardium. This procedure was done 
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from the base to the apex of the heart (every 60 heart sections) to track the entire microthread 
implantation. Figure 14 illustrates how the biological microthread implantation distance from the 
epicardium was calculated. The 0.5 mm scale bars were employed to determine the distance from the 
epicardium using Adobe Photoshop. The distances were determined by first determining the shortest 
distance from the outermost part of the epicardium to the innermost part of the endocardium, while 
crossing the centroid of the microthread. Once the endocardial distances were determined for the 
experiment, they were graphed (distance from endocardium vs. implantation distance). 
4.5: Statistical Analysis 
 Statistics were performed in this project using Microsoft Excel 2007 with the Analysis ToolPak. 
Statistical differences were determined using unpaired, two-tail, unequal variance t tests for two groups.  
All data was reported in the following format unless otherwise noted: mean ± SEM (standard error of the 
mean). All experiments had a minimum of n = 2. A p-value < 0.05 indicated a statistically significant 
difference between groups.   
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Figure 14: Microthread implantation tracking 
(5x magnification, Masson’s Trichrome staining, collagen microthreads are blue, fibrin microthreads are pink). The images are organized as follows: left (first): 
section containing biological microthread closest to base of the heart, right (last): section containing biological microthread closest to the apex of the heart. This 
figure illustrates how the biological microthread was implanted into the left ventricular wall of the rat heart. These images were used to determine the distance 
of the microthread from the innermost section of the endocardium. Each section is 480 µm apart.  
BASE APEX 
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4.4.5: Confocal microscopy 
Confocal microscopy was utilized for some of the images in this thesis due to the thickness of the 
heart sections. Confocal microscopy was used to visualize α-actinin/Hoechst stained sections with 
quantum dot loaded cells delivered to the heart and to produce three dimensional recreations of the 8 µm 
tissue sections which could be rotated to analyze the location of quantum dot signal relative to hMSC 
nuclei. All of the confocal images were taken with 20x, 40x, or 63x oil objectives. The confocal images 
were taken with a Leica TCS SP5 II point scanning confocal microscope. Once the slide was in place, the 
biological microthread was found and the implantation area was scanned for quantum dots through the 
microscope’s eyepiece. After a suitable area was found, the confocal system’s lasers were used to excite 
the sample and an image was displayed on the computer screen.  
Two lasers were utilized: a UV laser (405 nm) for the Hoechst dye and 655 ITK quantum dots 
and a 488 nm laser for the Alexa Fluor 488. Qdot 655 ITK quantum dots are excited from 400 - 650 nm 
and emit signal from 600 - 700 nm with maximum emission at 655 nm [86]. Hoechst 33342 dye is excited 
from 300 – 450 nm and emits signal from 355 – 650 nm, with maximum emission at 460 nm [90]. Alexa 
Fluor 488 is excited from 350-600 nm and emits signal from 488 – 650 nm, with maximum emission at 
519 nm [91] (see Figure 17). Each channel (Hoechst, quantum dot, and Alexa Fluor 488) had to be 
adjusted for gain and offset until the image was properly displayed. If a z-stack was desired, the 
beginning and end of the stack had to be chosen so that a thickness of the tissue section would be scanned 
by the microscope. The confocal software would determine the number of scans required to recreate a 
thickness of the tissue section (usually 80-150 images). A z-stack would then allow several options 
including a 3D rotation of the tissue section and a maximum projection of the tissue section (all pictures 
merged into a single image, see Figure 15). Spectral analysis was also utilized on several sections to 
reduce the autofluorescence of the heart tissue (see Figure 16).  
As described earlier, Alexa Fluor 488 and Hoechst 33342 dye have a wide spectral emission and 
therefore cause tissue autofluorescence and bleeding into other channels. Hoechst 33342 dye emits signal 
from 355-650 nm and Alexa Fluor 488 emits signal from 488-650 nm meaning that both stains emit 
signal from 488 – 650 nm (Figure 17). For spectral analysis, the entire potential emission spectrum was 
scanned by the microscope (5 nm per scan) and a spectral histogram was displayed and analyzed by the 
user. The desired spectral ranges were then chosen, and a majority of the autofluorescence was removed. 
This process was done for both the Hoechst and quantum dot channels (400 – 700 nm) and then the Alexa 
Fluor 488 channel (400-500 nm). 
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Figure 15: Confocal images before (left) and after (right) max projection 
(63x magnification, Hoechst dyed nuclei are blue, quantum dots are red) 
 
Figure 16: Confocal images before (left) and after (right) spectral analysis 
(63x magnification, Hoechst dyed nuclei are blue, Alex Fluor 488 stained α-actinin is green, quantum dots are red) 
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Figure 17: Spectral absorbance and emission curves for Hoechst 33342 (top left), Alexa Fluor 488 (top right), 
and Qdot 655 ITK quantum dots (bottom) 
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Chapter 5: Results  
5.1: Quantifying hMSC seeding on biological microthreads  
 The quantification of hMSC seeding on biological microthreads was required to calculate the 
hMSC delivery efficiency of the biological microthread implantation. The biological microthreads were 
stained with Hoechst dye and Phalloidin to qualitatively assess hMSC seeding (see Figure 18). The 
hMSCs appear to cover nearly the entire surface of the 8 fibrin, 4 collagen microthread bundle after 24 
hours of incubation in the bioreactor.  
 
Figure 18: Biological microthread seeding after 24 hours 
(10x magnification, Hoechst dyed nuclei are blue, Phalloidin stained f-actin filaments are green) 
 
Qualitative assessment confirmed that the hMSCs were being seeded on the biological 
microthreads. Quantitative assessment was done by trypsinizing the biological microthreads and counting 
the dislodged hMSCs with a hemocytometer. Counting was performed one day after seeding to coincide 
with the surgical implantation of microthread bundles seeded within the same batch. The results of these 
counts are shown in Table 2a. However the results of these counts were not utilized as the denominator in 
the microthread implantation efficiency calculations for several reasons. For the first two experiments 
(EXP0214 and EXP0215) the microthreads were not analyzed for any remaining attached hMSCs after 30 
minutes of trypsinization to ensure complete removal of cells from the microthread bundles prior to 
analysis. Also, in subsequent experiments, microthread bundles were agitated every 5 minutes during the 
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30 minutes trypsinization period to maximize hMSC detachment, which resulted in more consistent 
counts. Agitation and analysis of remaining microthread bundles was incorporated into the protocol and 
five additional microthread seeding experiments were performed. Although the same seeding conditions 
were used in EXP0214-EXP0219, the seeding experiments were not seeded at the same time as 
microthread implantation surgeries. The results of these seeding experiments are shown in Table 2b. 
These results were used to determine the average number of cells seeded on a 2 cm microthread bundle, 
which was subsequently used as the denominator for calculating the efficiency of biological microthread 
implantation. Based on these seeding experiments, it was determined that an average of 11,806 ± 3,932 (n 
= 20) hMSCs were seeded on the biological microthreads using the 24 hour bioreactor seeding technique. 
The implantation length and depth were utilized to estimate the total number of cells that were seeded on 
the length of microthread that was implanted in the rat heart (adjusted hMSC seeding, Table 3). The 
adjusted hMSC seeding count was always lower than the average microthread seeding count due to the 
fact that on average a 0.62 cm (out of a total microthread length of 2 cm) length of microthread was 
implanted into the rat heart. Adjusted hMSC seeding was calculated using Equation 3 as follows: 
 
𝐼𝑚𝑝𝑙𝑎𝑛𝑡  𝑙𝑒𝑛𝑔𝑡 𝑕
2 𝑐𝑚  𝑖𝑛𝑖𝑡𝑖𝑎𝑙  𝑚𝑖𝑐𝑟𝑜𝑡 𝑕𝑟𝑒𝑎𝑑  𝑙𝑒𝑛𝑔𝑡 𝑕
∗ 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑕𝑀𝑆𝐶𝑠 𝑜𝑛 𝑚𝑖𝑐𝑟𝑜𝑡𝑕𝑟𝑒𝑎𝑑 𝑏𝑢𝑛𝑑𝑙𝑒 𝑎𝑓𝑡𝑒𝑟 24 𝑕𝑜𝑢𝑟𝑠  
 
Equation 3: Adjusted hMSC seeding calculation 
 
 
Experiment Average Cell Number ± SD 
EXP0214 (n=2) 7,320 ± 6,619 
EXP0215 (n=2) 4,540 ± 2,517 
EXP0217 (n=2) 18,119 ± 16,915 
EXP0218 and EXP0219 
(n=2) 
15,951 ± 8,926 
Average (n=8 total) 11,483 ± 8,744 
Table 2a: Biological microthread hMSC seeding count (old counting protocol) 
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Experiment Average Cell Number ± SD 
Seeding Experiment 1 (n=4) 5,824 ± 2,457 
Seeding Experiment 2 (n=4) 10,260 ± 4,817 
Seeding Experiment 3 (n=4) 12,381 ± 4,313 
Seeding Experiment 4 (n=4) 16,966 ± 3,695 
Seeding Experiment 5 (n=4) 13,601 ± 4,377 
Average (n=20 total) 11,806 ± 3,932 
Table 2b: Biological microthread hMSC seeding count 
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Microthread 
implantation 
sample 
Implant length (cm) Implant depth (cm) (Implant length / initial 
thread length) * 
hMSCs on threads  
EXP0214 0.66 0.45 6,588 
EXP0215  0.44 0.28 4,203 
EXP0217 0.7 0.27 5,219 
EXP0218 0.64 0.4 6,048 
EXP0219 0.73 0.3 5,578 
Average 0.63 0.34 5,527 
 
Table 3: Adjusted number of hMSCs delivered on biological microthreads  
This table shows the values of the measurements taken to estimate the total number of cells seeded on the length of 
microthread that was implanted in the rat heart. The implant length was divided by 2 cm (the original length of the 
seeded microthread bundle) and multiplied by 11,806 (the average number of hMSCs on microthread bundles after 
24 hours of seeding). 
 
5.2: Quantifying hMSC delivery to the ventricular wall  
One of the main objectives of this thesis was to maximize the delivery of hMSCs to the left 
ventricular wall in the rat heart. A method was developed to estimate the number of hMSCs delivered to 
the rat heart as previously described. All experiments were histologically analyzed and the hMSC 
delivery distribution and efficiency were determined. The biological microthread implantation group (n = 
5) had a delivery efficiency of 63.6 ± 10.6% (see Table 4) and the intramyocardial injection group (n = 4) 
had a delivery efficiency of 11.8 ± 6.25% (see Table 5). Biological microthread implantation was 
significantly more efficient (p < 0.05, see Figure 19). The total number of cells engrafted in each group 
was also calculated (see Figure 20). The average number of cells engrafted for each biological 
microthread implantation was 3,527 ± 624. The average number of cells engrafted for each 
intramyocardial injection was 1,146 ± 547. Biological microthread implantation delivered significantly 
more hMSCs (p < 0.05). It should be noted that for the final intramyocardial injection surgery, there were 
no quantum dot loaded hMSCs engrafted in the ventricular wall. For this reason, there were only four 
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intramyocardial injection experiments analyzed. In terms of rat weight, the intramyocardial injection 
group rats had an average weight of 569 g and the microthread implantation group rats had an average 
weight of 576 g (see appendix D for data). Heart rate prior to euthanasia was also determined for the rats 
in the two groups. However, for the first two microthread implantation experiments a pulse oximeter was 
not available so no data was acquired. The average heart rate for the intramyocardial injection group was 
196 beats per minute. The average heart rate for the microthread implantation group was 220 beats per 
minutes (see appendix D for data).   
 
 
 
Figure 19: hMSC engraftment rate (%): microthread implantation vs. intramyocardial injection 
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Figure 20: hMSC engraftment number comparison: microthread implantation vs. intramyocardial injection 
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The hMSC delivery length, the length of heart tissue from base to apex to which hMSCs were 
delivered, was compared between the intramyocardial injection and microthread implantation groups 
next. Quantum dot loaded hMSCs were delivered to an average length of 0.55 ± 0.06 cm for the 
microthread implantation group (see Table 4) and 0.33 ± 0.13 cm for the intramyocardial injection group 
(see Table 5). Human mesenchymal stem cells were delivered to a significantly longer length with the 
microthread implantation group (p < 0.05, see Figure 21). 
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Experiment Total hMSCs Delivered Engraftment Rate 
EXP0214 2,670 41% 
EXP0215  1,828 43% 
EXP0217 3,709 71% 
EXP0218 3,896 64% 
EXP0219 5,526 99% 
Average 3,527 64% 
 
Table 4: Microthread implantation experiment cell delivery results 
This table  shows the total number of hMSCs delivered to the rat heart and the total delivery efficiency for each 
biological microthread implantation as a percentage of cells delivered per microthread bundle implanted (see Table 
3).   
 
 
Experiment Total hMSCs Delivered Delivery Efficiency 
EXP0220 752 7.52% 
EXP0221  2,779 27.8% 
EXP0224 461 4.61% 
EXP0225 591 5.91% 
Average 1,146 11.8% 
 
Table 5: Intramyocardial injection experiment cell delivery results 
This table shows the total number of hMSCs delivered to the rat heart and the total delivery efficiency for each 
intramyocardial injection experiment. Delivery efficiency was calculated as a percentage of 10,000 hMSCs injected 
per heart sample.  
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Figure 21: hMSC delivery length comparison: microthread implantation vs. intramyocardial injection 
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5.3: hMSC delivery distribution 
The hMSC delivery distribution was determined by counting the number of hMSCs delivered in 
three consecutive rat heart sections every sixty sections after histology and staining were completed. In 
some cases (EXP0218) the microthread bundle entered the ventricular cavity due to surgical error and 
resulted in several sections not containing delivered cells (see Figure 22 for histology). Despite this 
imperfect implantation, cell delivery efficiency was still relatively high (64%). The hMSC delivery 
distribution graphs for EXP0214-EXP0219 (microthread bundle implantation, Figure 23) demonstrate a 
larger number of cells delivered to the base, where the suture needle was initially inserted for surgical 
implantation. Despite some shearing, cell delivery throughout the implantation length was still observed.  
The hMSC delivery distributions of the intramyocardial injections varied considerably from experiment to 
experiment (in terms of the number of cells delivered per 24 µm of heart tissue and total delivery length, 
see Figure 24). 
 
Figure 22: Biological microthread bundle delivered to ventricular cavity 
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Figure 23: hMSC delivery distributions – microthread implantations 
The following graphs show the distribution of delivered hMSCs to the rat heart for the five individual hMSC-seeded 
microthread bundle implantation surgeries (EXP0214-EXP0219). The implantation distance (x axis) starts from the 
section of the biological microthread implanted closest to the base of the heart (where the microthread entered the 
heart) and ends at the biological microthread implanted closest to the apex of the heart (where the microthread 
exited the heart). 
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Figure 24: hMSC delivery distributions – intramyocardial injections 
The following graphs show the distribution of delivered hMSCs to the rat heart for the four intramyocardial 
injections (EXP0220, 221, 224, 225). The implantation distance (x axis) starts from where the quantum dot loaded 
hMSCs were delivered closest to the base of the heart and ends where the final quantum dot loaded hMSCs were 
delivered, closest to the apex of the heart. 
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The combined delivery distributions of the microthread implantation and intramyocardial 
injection groups illustrated the average number of cells delivered along the implantation length: at the 0%, 
25%, 50%, 75%, and 100% points of the total delivery length. These graphs demonstrate the cell delivery 
patterns of the two groups. As shown in Figure 25, a high percentage of the cells were delivered close to 
the entry point of the microthread bundle. At the 50% point, there was a steep reduction in the cell 
delivery percentage because the microthread bundle entered the ventricular cavity on several surgeries. 
Figure 26 shows the combined delivery distribution of the intramyocardial injection group. A majority of 
the cells were delivered at the 50% point, where the syringe needle released the hMSC suspension into the 
heart wall. Fewer cells were delivered towards the apex and the base of the heart (from the 50% point). 
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Figure 25: Microthread Implantation – Combined Delivery Distribution 
 
 
Figure 26: Intramyocardial Injection – Combined Delivery Distribution 
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5.3.1 Biological microthread implantation tracking 
Implantation tracking allowed the estimation of the location of the delivered hMSCs for the 
biological microthread implantation experiments. The implantation tracking graphs depict the location of 
the biological microthread bundles within the rat myocardium (in the Masson’s Trichrome stained heart 
sections) at 480 µm increments and the number of quantum dot loaded nuclei counted at each of these 
480 µm increments. The Masson’s Trichrome stained sections were taken directly adjacent to the Hoechst 
dye stained sections so that the location of the delivered cells could be estimated. Implantation tracking 
also quantitatively illustrated the success (in terms of localization) of an implantation experiment. Figure 
27 demonstrates the differences between each microthread implantation experiment. The distance from 
the endocardium is shown as a percentage of the left ventricular wall thickness in these figures. One 
hundred percent distance means the microthread bundle is entirely out of the epicardium and 0% distance 
means the microthread bundle is in the innermost part of the endocardium. In some cases the biological 
microthread bundle entered the left ventricular cavity. In these cases, the distance from the endocardium 
was still considered 0%. 
 
Figure 27: Microthread implantation tracking 
The following five graphs (EXP0214-0219) show the location (in the left ventricular wall) of the biological 
microthread implantations and the number of delivered hMSCs in each location. The red line illustrates the distance 
of the biological microthread from the innermost part of the endocardium of the left ventricular wall.  
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 Table 6 illustrates the number of cells delivered to the endocardium, myocardium, and 
epicardium of the left ventricular wall for each biological microthread implantation experiment. The 
endocardium was defined as the region spanning 0 to 33.3% of the distance from the innermost part of the 
left ventricular wall. The myocardium was defined as the region spanning 33.4 to 66.6% of the distance 
from the innermost part of the left ventricular wall. The epicardium was defined as the region spanning 
66.7 to 100% of the distance from the innermost part of the left ventricular wall.  
 The implantation tracking graphs illustrated the differences between each of the biological 
microthread implantations. The first noticeable trend was that only two out of the five biological 
microthread implantations had similar implantation tracking graphs (EXP0214 and EXP0218). These two 
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experiments maximized biological microthread implantation to the endocardium. EXP0217, perhaps the 
most puzzling experiment, had the most unexpected implantation tracking graph. Toward the center of the 
implantation, after the biological microthread entered the innermost part of the endocardium, the 
biological microthread bundle traveled 56% of the left ventricular wall thickness towards the epicardium 
over the course of 0.36 mm of heart tissue. The biological microthread bundle then traveled back towards 
the endocardium and then continued to exit the heart. This unexpected “zig-zag” pattern may have been 
the result of a surgical mistake during the implantation - the surgeon not passing the microthread bundle 
through the heart in a steady motion.  
The percentage of hMSCs delivered to the endocardium, myocardium, and epicardium 
determined how effectively the biological microthread bundles can target transmural hMSC delivery. A 
goal of this project was to establish the ability of the biological microthread bundles to deliver hMSCs to 
the endocardium. There were 1,691 ± 448 hMSCs delivered to the endocardium for each biological 
microthread implantation. There were 1,152 ± 391 hMSCs delivered to the myocardium per biological 
microthread implantation and 683 ± 352 hMSCs delivered to the epicardium for each biological 
microthread implantation (see Figure 28).  
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Experiment 
hMSCs Delivered to 
Endocardium (%) 
hMSCs Delivered to 
Myocardium (%) 
hMSCs Delivered to 
Epicardium (%) 
EXP0214 1,930 (72.3%) 690 (25.8%) 50 (1.9%) 
EXP0215  445 (24.3%) 477 (26.1%) 906 (49.6%) 
EXP0217 1,790 (48.3%) 1,720 (46.4%) 199 (5.4%) 
EXP0218 3,142 (80.6%)  460 (11.8%) 294 (7.5%) 
EXP0219 1,150 (20.8%) 2,410 (43.6%) 1,966 (35.6%) 
Average 1,691 (49.3%) 1,152 (30.8%) 683 (20%) 
 
Table 6: Localization of delivered hMSCs 
 
 
Figure 28: hMSC delivery localization to endocardium, myocardium, and epicardium 
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Chapter 6: Discussion 
The experiments completed during this project have illustrated that biological microthreads can 
be seeded with over 11,000 hMSCs and implanted successfully in the rat heart. It has also been 
established that hMSCs can be delivered to the myocardium or endocardium with biological 
microthreads. Biological microthreads have also been shown to deliver cells consistently along the entire 
length of the implantation, despite some cell loss at the entry point. Finally, biological microthread 
mediated hMSC delivery has been shown to be more efficient than intramyocardial injection after one 
hour of implantation. The importance of these results will be discussed in this section.  
6.1 Biological Microthread Cell Seeding  
Determining how many cells were being seeded on the biological microthread bundles was more 
difficult than initially anticipated. Murphy et al. were able to estimate the number of hMSCs seeded on a 
bundle of four fibrin microthreads by staining with Hoechst dye followed by microscopy to analyze cell 
number [16]. However, with a larger bundle size (eight fibrin and four collagen microthreads) several 
complications became apparent. The first problem was the diameter of the larger microthread bundle. 
Since the bundle of 12 biological microthreads had an average diameter of 0.7 mm, counting all of the 
cells on the surface of the bundle was nearly impossible due to the substantial depth of field. Since the 
microthreads were bundled, they also overlapped each other and covered large populations of cells. 
Coverslipping such a large specimen was difficult and usually resulted in an excessive amount of air 
under the coverslip which degraded the sample over time. Due to these difficulties a different method was 
utilized, as discussed earlier (hemocytometer method), to count the number of cells seeded on the 
biological microthread bundles. 
On average, 11,806 cells were seeded on 2 cm long biological microthread bundles utilized for 
this project. In the future, a larger seeding number may be desired to further increase the improvement of 
cardiac function post-MI. Murphy et al. demonstrated a nearly three-fold increase in cells seeded per 
microthread bundle after five days, when compared to the one day time point (3,344 versus 9,644 cells) 
[16]. If it is assumed that the same would occur with the microthread bundles seeded with hMSCs for this 
project, 30,000 cells could potentially be seeded on a single microthread bundle (this has been done after 
a single day of seeding but only for one sample). Since only a part of the microthread bundle was actually 
implanted into the rat heart, 12,000 cells could potentially be delivered to the rat heart with the increased 
seeding time ([5,527 / 11,803] x 30,000). Another method to increase the number of cells delivered with 
biological microthreads could be to implant more seeded biological microthread bundles. This method 
would also increase the area of myocardial tissue that receives hMSCs. However, this method would most 
likely be more effective in a larger animal model (dog, pig, etc.) due to the size of the injury that would be 
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created in a small rodent heart. A final potential method of increasing cell delivery would be to increase 
the number of fibrin microthreads and decrease the number of collagen microthreads used in the 
microthread bundle. This could potentially increase hMSC seeding on the microthread bundle.   
Qualitative analysis of the Hoechst and phalloidin stained biological microthread bundle 
illustrated several important points. The first observation was that the entire length of the biological 
microthread bundle was seeded with hMSCs (although the hMSCs did not cover the entire surface area of 
the biological microthread bundle). Other methods that were attempted include the PDMS 
(Polydimethylsiloxane) v-well method and post method (the post method was used to seed Murphy et 
al.’s fibrin microthread bundles). The post method was attempted first because of its simplicity and 
effectiveness with the smaller fibrin microthread bundles. The post method required the microthread 
bundle to be attached to a suture needle and then glued onto a stainless steel washer. The washer was then 
placed in a 6 well plate and a 12 mm diameter Thermanox coverslip glued onto a PDMS post was placed 
underneath the center of the microthread bundle. The post was a Thermanox coverslip glued onto a 
PDMS cylindrical post that raised the coverslip to the level of the microthread bundle. After placement, 
100 μL of cell suspension was pipetted directly onto the microthread bundle, which rested on the 
Thermanox coverslip. The PDMS v-well seeding method was designed so that a microthread bundle 
could be split into several smaller bundles to maximize the surface area exposed for seeding. The twelve 
equally sized v-shaped orifices in the PDMS v-well allowed the microthread bundle to be split into up to 
twelve separate microthreads or small microthread bundles. The protocol for seeding the v-well method 
was identical to the post method except for the use of the v-well. Both methods had the same critical 
flaws. As shown in Figure 29, only the center of the microthread bundle was actually seeded for both 
methods. Also, more than half of the surface of the microthread bundle was not being utilized because of 
the seeding design (the bottom half was covered with either a v-well or post, see Figure 30).   
     
Figure 29: Previously attempted microthread seeding methods: post method (A) and v-well method (B). 
  
Stainless 
steel washer 
Microthread 
bundle 
Coverslip 
Suture needle 
PDMS v well 
hMSC 
suspension 
A B 
66 
 
 
 
Figure 30: Biological microthread seeding after 24 hours – PDMS v-well method 
(10x magnification, Hoechst dyed nuclei are blue, Phalloidin stained f-actin filaments are green). This picture 
illustrates the imaging difficulty when working with a bundle of 12 microthreads. Half of the image is clearly out of 
focus and the microthreads are stacked on top of one another, making it impossible to see all of the seeded cells. In 
terms of seeding, the bottom half of the microthread bundle has very few cells attached compared to the top half.    
 
6.2 hMSC Delivery to the Heart  
6.2.1 hMSC delivery efficiency 
The main objective of this project was to develop a more efficient means of delivering hMSCs to 
the heart. As discussed in the background, current delivery methods have low cell engraftment rates. 
While improving delivery efficiency, the new delivery method had to facilitate surgical simplicity and 
reproducibility. Biological microthread implantation was chosen as a novel approach to cardiac cell 
delivery because of its relative surgical simplicity, similarity to suture, and ability to deliver cells near the 
endocardium.  Intramyocardial injection was chosen as a comparison hMSC delivery method since it is 
widely utilized by researchers. In terms of protocol, 10,000 hMSCs were injected into the rat heart for 
intramyocardial injection because that was the estimated number of cells that could be delivered with 
seeded biological microthreads. However, since only 0.63 cm of microthread (out of 2 cm) was actually 
implanted into the heart on average, the adjusted microthread-mediated cell delivery was 5,527.   
Each group (intramyocardial injection and biological microthread) was intended to have a sample 
size of 5. However, on the final intramyocardial injection experiment (EXP0226) there were no quantum 
dot loaded hMSCs found in the heart. This was most likely due to intracavitary injection of the hMSCs 
Top 
Bottom 
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(into the left ventricle) which resulted in the cells being washed away into the blood circulation. The 
ejection of the hMSC suspension due to ventricular contraction was also possible. Since the final 
experiment had a delivery efficiency of 0%, we did not include it in our statistical analysis because it was 
most likely due to surgical error. The intramyocardial injection group had a sample size of 4, while the 
biological microthread group had a sample size of 5. However, the experimental results illustrate an 
important point. Intramyocardial injection was more difficult to perform successfully than biological 
microthread implantation. Five out of five of our microthread implantations were successful, while four 
out of five intramyocardial injections were successful. The intramyocardial injections often lead to 
excessive bleeding due to puncturing a major blood vessel or entering the ventricular cavity with the 
syringe needle. The 80% success rate was mostly due to swift actions by the surgeon to minimize 
bleeding. Biological microthread implantation also resulted in the microthread entering the ventricular 
cavity or puncturing a major blood vessel on some occasions but did not cause excessive bleeding. This 
may be due to the fact that fibrin serves as a blood clot during the natural wound healing process and 
therefore halted the bleeding almost immediately.      
The surgical implantation of biological microthread bundles in the rat heart was evaluated by 
comparing the engraftment rate of each microthread implantation. For EXP0214 and EXP0218, the 
surgeon attempted to implant the biological microthread bundle directly into the endocardium. In both 
cases, the biological microthread bundle entered the ventricular cavity and reduced the number of hMSCs 
engrafted into the heart wall. For the biological microthread implantation that had the highest engraftment 
rate, EXP0219, the surgeon attempted to implant the microthread bundle into the mid-myocardium. 
Therefore, future biological microthread implantation surgeries should focus on delivering the maximum 
length of microthread to the heart wall and not enter the ventricular cavity. Different suture needle sizes 
and shapes can be utilized to reduce microthread delivery to the ventricular cavity. The microthread 
bundles in this project were attached to size 18 tapered half-circle suture needles. A smaller suture needle 
(size 20 or above) that is 3/8 circle could potentially reduce delivery to the ventricular cavity.  
Several complications with sectioning nearly the entire heart for each experiment (to calculate 
delivery efficiency) became apparent. The first issue was the amount of time required to histologically 
section a single heart. Four hundred eighty to 903 sections were cut per biological microthread 
implantation sample, while 183 to 543 sections were cut per intramyocardial injection sample. On some 
occasions it took several weeks before the results of a single surgery were completely analyzed. The 
analysis included histological sectioning, Hoechst staining, Masson’s trichrome staining, α-actinin 
staining, and analyzing three sections every sixty sections for hMSC delivery count and biological 
microthread location in the heart wall. This meant that the surgeon did not know whether or not they had 
successfully implanted a biological microthread until several weeks passed. Another issue with sectioning 
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the entire heart was analyzing the sections after staining. The cryostat that was used for histologically 
sectioning the rat hearts occasionally cut sections of inconsistent thickness (if optimal cutting temperature 
was not maintained by the cryostat). Acquiring images of these sections usually resulted in a time 
consuming balancing act, focusing on the region of interest while a large portion of the section remained 
out of focus. Radiolabeled hMSCs [53] and MRI-labeled hMSCs [92] could have been utilized to reduce 
the time required for the complete analysis of hMSC delivery efficiency. However, both methods require 
a substantial initial investment of time and funding.   
Quantum dots were chosen for hMSC tracking, when determining cell engraftment rate in the rat 
heart, for several reasons. Quantum dot loading hMSCs was a straightforward protocol and was easily 
reproducible (with 98% loading efficiency); involving simply adding quantum dots to the hMSC media 
and waiting 24 hours. Quantum dots do not affect hMSC differentiation or prevent proliferation in vitro 
[87]. Quantum dots are also not taken up by adult cardiac myocytes in vitro and cardiac cells in vivo and 
do not transfer to nearby cells. Quantum dot labeled hMSCs also retain quantum dots for more than six 
weeks in vitro. One of the most important advantages of quantum dots is the relatively large Stokes shift. 
Since there is a large gap between the maximum excitation and emission wavelengths, quantum dots are 
easily spotted in the heart tissue, due to minimal tissue autofluorescence and bright concentrated 
emission. When the three rules of counting are applied (see materials and methods section), quantum dots 
can be utilized to estimate cell engraftment rate. These rules are required because the most apparent 
disadvantage of quantum dots is the inability to see the exact outline of individual quantum dot loaded 
cells. This disadvantage is especially limiting when quantum dot loaded cells are in close proximity, and 
individual cells cannot be deciphered. In such cases, the number of quantum dot loaded cells counted 
must be conservative to eliminate the chances of counting non-quantum dot loaded cells. 
Other methods of hMSC tracking are available that have some distinct advantages and could 
potentially help distinguish individual hMSC nuclei. Anti-NuMA (Nuclear Mitotic Apparatus Protein) 
human specific primary antibody could have been utilized to stain the hMSCs in our rat heart sections 
[93]. Using anti-NuMA would have allowed identification of individual hMSC nuclei and could have 
potentially improved counting accuracy in areas where hMSCs were in close proximity. Anti-NuMA 
would have also shown that the hMSCs that were delivered were in fact human cells. The disadvantages 
of using anti-NuMA include potential difficulty finding positive signal due to the autofluoresence of the 
heart tissue (if using a fluorescent secondary antibody such as Alexa Fluor 488) and an increase in the 
time required to complete tissue analysis (counting hMSCs delivered to the rat heart) due to the addition 
of another staining protocol.           
Despite delivering fewer cells initially, significantly more cells were engrafted in the biological 
microthread group. It should be noted that the average of 3,527 hMSCs engrafted for the biological 
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microthread implantations could potentially be improved by simply increasing the seeding time on the 
biological microthreads. If the increased seeding time is not successful, new approaches to implantation 
could be employed, including implanting multiple biological microthreads bundles. The intramyocardial 
injection group exhibited an engraftment rate of 11.8%, which was comparable to the engraftment rate 
reported by other researchers (11%) [53]. Since only 1,180 hMSCs engrafted in the intramyocardial 
injection group on average, a higher concentration of cells could be injected to increase the cell 
engraftment number.  
The number of hMSCs delivered to the rat heart was determined by manually counting quantum 
dot loaded hMSC nuclei in 24 µm of tissue every 480 µm. This meant that only 5% of the total heart 
length (from base to apex) was analyzed for each microthread implantation and intramyocardial injection 
sample. Future studies could focus on analyzing a single section (8 µm of tissue) at shorter intervals to 
decrease the distance between each of the analyzed tissue sections while not greatly increasing the 
percentage of tissue analyzed. The assumption that there was a linear relationship between each of the 
480 µm increments was not validated. This aspect of this research should be pursued and the relationship 
between each of these points could potentially be determined by analyzing the heart sections at shorter 
intervals (40 µm for example).    
Cardiac functional analysis (left ventricular ejection fraction, stroke volume, etc.) must be 
performed on the biological microthread implantation subjects to evaluate the effect of microthread 
bundle delivery to the myocardium (the left ventricular defect would be caused by ligating the left 
anterior descending coronary artery). The occlusion would then be removed and the blood flow would be 
restored prior to biological microthread implantation. The infarcted myocardium would be analyzed with 
or without hMSC delivery to analyze the effect of hMSCs and delivery method on cardiac function. The 
biological microthread bundles would be implanted in Sprague-Dawley rats with induced myocardial 
infarctions. The biological microthread bundle will initially be passed through the infarction to maximize 
hMSC delivery. However, this strategy may have to be altered due to reduced blood flow in the infarction 
zone and a reduction in the thickness of the heart wall with myocardial infarction. The implantation 
location will be an important factor in the effectiveness of biological microthread mediated hMSC 
delivery.  
High Density Mapping (HDM) would be utilized to determine regional systolic function of the 
myocardial infarction before and after hMSC therapy. HDM allows the analysis of a small region (less 
than 10 mm
2
) of the heart, by acquiring images of the beating heart and then allowing the user to pick a 
region of interest for software analysis [94]. The software then outputs regional stroke work which can be 
utilized to determine cardiac function in the region of interest [95-98]. The HDM method has been 
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utilized to calculate the regional function in the in vivo porcine model, isolated rabbit heart, and canine in 
vivo model [50, 99, 100]. 
6.2.2 hMSC delivery distribution 
  Another major goal of this project was to determine if hMSCs were being delivered throughout 
the length of the heart where the biological microthread was implanted or cells injected intramyocardially. 
If cells were being delivered to a narrow area of the heart but at a high efficiency, the delivery method 
was considered inefficient. The goal was to deliver a consistently high number of cells across an 
extensive length of heart tissue (from apex to base). Biological microthread implantation delivers hMSCs 
more efficiently, over a longer length in the heart tissue, and more hMSCs per 24 µm of heart tissue than 
intramyocardial injection.   
The intramyocardial injection delivery distribution graphs demonstrate some of the characteristics 
of this delivery method. The cell delivery distribution appeared to be random and the surgical procedure 
was difficult to improve. The delivery distributions had random areas with no cell delivery in some cases 
(EXP0220 and EXP0224). The hMSC delivery length varied a great deal, 1,464 – 4,344 µm for the 
intramyocardial injections. The biological microthread implantation, in contrast, allowed the surgeon to 
customize the delivery length by implanting more or less of the biological microthread bundle. 
 The biological microthread implantation delivery distributions exhibited some important 
characteristics. The first characteristic was found in all of the biological microthread delivery 
distributions: more cells were delivered near the implantation entry site at the base of the heart (especially 
close to the initial insertion area, initial 24 – 1,464 µm of heart tissue). This trend may have been the 
result of cell shearing when the biological microthread first entered the cardiac tissue. The biological 
microthread was first inserted into the base-side of the heart and then removed from the apex-side of the 
heart. A second notable characteristic was an increase in the number of cells delivered on the end of the 
apex-side (usually the final 960 µm) of the implantation for some of the experiments. This trend may 
have been the result of cell shearing when the biological microthread exited the tissue. The final 
characteristic was a lack of cell engraftment in the heart wall in the center of the biological microthread 
implantation (1,920 µm of tissue for a single microthread implantation sample). This single occurrence 
was due to the biological microthread entering the ventricular cavity.  
 The intramyocardial injection delivery distributions were more difficult to analyze than the 
biological microthread implantations. The first issue was not knowing where the hMSCs were initially 
injected into the heart. Despite an effort to determine the injection location, the exact location could not 
be determined for each experiment. In terms of searching for delivered quantum dot loaded hMSCs in the 
heart wall, such efforts were very time consuming due to the random location of delivered hMSCs. The 
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entire rat heart was scanned with a fluorescent microscope for every analyzed section. The hMSCs were 
delivered to the endocardium, myocardium, and epicardium, with no discernable trend. In some cases 
there were no quantum dot loaded hMSCs present in one set of heart sections, but several present in the 
next set (480 µm apart). This random trend required excessive sectioning of the rat heart, even when there 
were no quantum dot loaded hMSCs present in several previous sets of sections. EXP0226, the failed 
intramyocardial injection experiment, illustrated all of the difficulties of analyzing the intramyocardial 
injection experiments. Four hundred eighty sections were cut for this experiment and all were analyzed, 
section by section, for delivered hMSCs. We did not find a single quantum dot loaded hMSC in all of 
these sections. The cell delivery length also varied greatly, despite an equal volume of injected cell 
suspension for each injection, and did not always dictate the delivery efficiency of an experiment. Cell 
delivery length could potentially be improved by passing a suture needle through the heart wall and 
injecting hMSCs into the cavity that was created to increase the amount of space available for the hMSC 
to engraft. EXP0221 had the highest delivery efficiency (27.8%) but did not deliver cells to the longest 
length of tissue (0.34 cm). EXP0220 and EXP0224 delivered hMSCs to a longer length of tissue, 0.43 cm 
and 0.39 cm respectively, but had lower delivery efficiencies of 7.5% and 4.6%.   
Cell shearing can potentially be avoided by developing a sheath (biomaterial or polymer) to 
protect the cell-seeded biological microthread. The sheath would serve as a protective barrier for the 
hMSC seeded biological microthread bundle during the process of implantation into the left ventricular 
wall. The sheath could either be used in the seeding process as a bioreactor or placed over the biological 
microthread after seeding. The sheath would also have to be firmly attached to the suture needle without 
adversely affecting the seeded biological microthreads. After implantation, the sheath would be removed 
to ensure cell viability, minimize immune response, and ensure efficient cell delivery to the ventricular 
wall. A material such as polytetrafluoroethylene (PTFE) could potentially be utilized to sheath the 
biological microthread after seeding due to its low coefficient of friction. The low coefficient of friction 
would aid in the removal of the sheath post-implantation, reducing cell shearing when the sheath is 
removed, and decreasing the difficultly of implanting a sheathed biological microthread bundle. If the 
sheath was not used as a bioreactor, the current bioreactor seeding method could be employed to seed the 
biological microthreads with hMSCs. If the sheath was used as a bioreactor, new seeding experiments 
would be required to ensure proper hMSC seeding on the biological microthread (and not on the sheath). 
The inner and outer diameter of the sheath would also have to be an optimal size to minimize injury to the 
heart, minimize cell shearing during the removal of the sheath, and maximize cell seeding on the 
biological microthread. The sheathed biological microthread bundle has potential to be an efficient hMSC 
delivery method that can consistently deliver cells to the infarcted myocardium.   
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6.2.3 Microthread implantation tracking 
Microthread implantation tracking established the location of the biological microthread bundle 
relative to the epicardium (outer third) and endocarium (inner third) of the left ventricular wall. Since the 
delivered hMSCs were found in close proximity of the biological microthread implantation (see Figure 
31), Masson’s trichrome stained sections were analyzed for the location of the implanted microthread. It 
was assumed that the location of the biological microthread indicated the location of hMSC delivery (see 
Figure 31). The distance from the epicardium and endocardium was stated as a percentage of the left 
ventricular wall thickness. When the implantation tracking graph was combined with the delivery 
distribution graph for a given experiment, the number of cells delivered to each third of the left 
ventricular thickness could be determined.   
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Figure 31: hMSCs delivered in close proximity to biological microthread bundle 
(40x magnification [top left], 63x magnification [top right], Hoechst dyed nuclei are blue, quantum dots are red, 
DIC overlay). (20x magnification [bottom left], 63x magnification [bottom right], Hoechst dyed nuclei are blue, 
quantum dots are red). White arrows indicate the location of quantum dot loaded cells. White dashed outlines 
indicate the location of the biological microthread bundles. 
 
Several complications arose as the heart sections were being analyzed. Some heart sections were 
smaller than others even when they were only 480 µm apart. This inconsistency can be attributed to the 
cryostat, which on occasion has cut sections of varying thickness (in some cases up to 3 µm more or less 
than the intended 8 µm thickness). Some heart sections also detached from the microscope slides during 
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staining (partially and fully), which resulted in the tissue folding on itself or complete tissue loss. These 
tissue sections were never used for analysis. The implanted biological microthread bundles also moved 
during sectioning on some of the heart sections. Since there were three heart sections on each slide, at 
least one section (out of the three) always had a biological microthread bundle that did not move during 
sectioning. On other occasions, the biological microthread bundle entered the ventricular cavity. When 
this occurred, the biological microthread bundle occasionally could not be found and it was assumed that 
the bundle was located 100% of the left ventricular wall thickness from the epicardium and 0% of the 
wall thickness from the endocardium. One of the implantation tracking graphs (EXP0217) also depicted 
the biological microthread bundle moving out and into the ventricular wall for a length of the 
implantation. This unexpected occurrence may have been due to several factors including: the cryostat 
cutting heart sections of various thicknesses and potentially not cutting the entire surface of the heart or 
difficulty passing the biological microthread bundle through the ventricular wall. Embedding the heart in 
paraffin may have prevented many of these complications, but was not done because of incompatibility 
with quantum dots. The quantum dots located in the loaded hMSCs faded several days after being 
embedded in paraffin.  
6.3 Microscopy  
Microscopy played a pivotal role in the completion of this project. Several different microscope 
types were used for different reasons throughout the project: an inverted microscope was used to ensure 
that hMSCs were quantum dot loaded prior to seeding a microthread bundle or trypsinizing hMSCs prior 
to injection; an upright microscope was used to count the number of hMSCs delivered to the heart wall, 
determine the location of the microthread implant, and acquire images of the hMSC seeded biological 
microthreads; and a confocal microscope was used to further study quantum dot loaded cells that were 
delivered to the heart. Each microscope type had its limitations. The upright and inverted microscopes 
could only focus on a narrow depth of field, which complicated acquiring images of quantum dot loaded 
hMSCs on some occasions. The upright and inverted microscopes also could not perform spectral 
analysis, which meant that tissue/microthread autofluorescence was nearly impossible to overcome. Only 
the inverted microscope could be used to acquire images of live cells since they were on the bottom of 
T75 flasks. The point scanning confocal microscope usually required a much longer time investment, 
especially when performing a z-stack or spectral analysis, than the upright and inverted microscopes, 
which resulted in fewer acquired images. Performing a z-stack on anything over 150 µm (at 40x 
magnification) was also not possible due to the limitations of the confocal microscope and software. 
Therefore a confocal image of the entire depth of the hMSC seeded biological microthread (over 700 µm 
diameter) was not possible with any oil objective (20x-63x).     
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The z-stacks, acquired with a confocal microscope, illustrated several points about quantum dots: 
quantum dots may look like they are in the cell’s nucleus, but are actually in the cytoplasm on top of the 
nucleus; quantum dots can be on a completely different plane than the same cell’s nucleus, making it look 
like a cell is or is not quantum dot loaded under a non-confocal microscope; quantum dots can span over 
nearly a an 8 µm thickness, which means that all quantum dots in a cell cannot be captured with a single 
image (a z-stack is required). Since the images used to perform the hMSC delivery count to the heart were 
taken with an upright microscope, some quantum dot loaded cells may not have been detected due to the 
limitations of the microscope. The lack of detection could have been due to several reasons including: 
only a faint part of the quantum dot signal being in focus, the visible signal not being adjacent to the 
loaded nucleus due to focal plane, and difficulty analyzing three dimensional “quantum dot clouds” with 
an upright microscope, causing an overly conservative count of quantum dot loaded cells (z-stack is 
required for a 3D image). Most of these problems were anticipated but could not be overcome due to time 
limitations (hundreds of images were taken for the analysis of all nine surgeries). The quantum dot 
counting rules, as discussed earlier, were established to minimize the chances of over-estimating the 
number of cells delivered to the heart. The actual number of cells delivered to the heart wall could have 
been higher than reported in this thesis for each experiment.   
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Conclusion 
Biological microthreads were developed into a novel cardiac delivery method that is surgically 
simple to implant and can be seeded with hMSCs. We have demonstrated that biological microthread 
mediated hMSC delivery is more efficient and can deliver cells over a longer length of tissue than 
intramyocardial injection. We were also able to deliver a higher quantity of hMSCs to the endocardium 
and myocardium, effectively targeting those layers of the ventricular wall with biological microthread 
hMSC delivery. This delivery system may lead to improved treatment for millions of patients suffering 
from myocardial infarction or heart failure.       
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Appendix A: Microthread Seeding Counts 
Experiment 
Hemacytometer 
count 
Trypsinized thread cell 
count 
Total cell 
seeding 
0214 12,000 
 
12,000 
 
2,640 
 
2,640 
0215 6,320 
 
6,320 
 
2,760 
 
2,760 
0217 30,080 
 
30,080 
 
4,032 2,127 6,159 
0218 and 0219 22,200 63 22,263 
 
9,120 520 9,640 
Seeding 
Experiment 1 
7,560 60 7,620 
 
1,050 1,149 2,199 
 
6,400 145 6,545 
 
6,560 370 6,930 
Seeding 
Experiment 2 
3,533 30 3,563 
 
14,896 32 14,928 
 
11,777 170 11,947 
 
10,577 26 10,603 
Seeding 
Experiment 3 
15,200 51 15,251 
 
15,333 18 15,351 
 
6,066 101 6,167 
 
12,720 33 12,753 
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Seeding 
Experiment 4 
12,740 77 12,817 
 
15,360 44 15,404 
 
18,200 38 18,238 
 
21,312 92 21,404 
Seeding 
Experiment 5 
11,250 22 11,272 
 
16,100 50 16,150 
 
8,700 19 8,719 
 
18,200 61 18,261 
Average 
 
230 11,685 
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Appendix B: hMSC Delivery Number Calculation  
EXP0214 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 6 
 
10.5 210 
Slide 21 15 
 
10.5 210 
Slide 41 6 
 
14.5 290 
Slide 61 23 
 
13.5 270 
Slide 81 4 
 
4 80 
Slide 101 4 
 
3 60 
Slide 121 2 
 
2.5 50 
Slide 141 3 
 
5 100 
Slide 161 7 
 
13.5 270 
Slide 181 20 
 
19.5 390 
Slide 201 19 
 
34.5 690 
Slide 221 50 
 
50 50 
Total cells delivered 
  
2670 
 
EXP0215 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 15 
 
17.5 350 
Slide 21 20 
 
12.5 237.5 
Slide 40 5 
 
5.5 115.5 
Slide 61 6 
 
5 100 
Slide 81 4 
 
4.5 99 
Slide 103 5 
 
6.5 130 
Slide 123 8 
 
12 240 
Slide 143 16 
 
26 520 
Slide 163 36 
 
36 36 
Total cells delivered 
  
1828 
 
 
 
 
 
 
 
 
 
 
85 
 
EXP0217 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 5 
 
7.5 150 
Slide 21 10 
 
8.5 170 
Slide 41 7 
 
9.5 190 
Slide 61 12 
 
7.5 150 
Slide 81 3 
 
4.5 90 
Slide 101 6 
 
9 180 
Slide 121 12 
 
27.5 550 
Slide 141 43 
 
53 1060 
Slide 161 63 
 
56 1120 
Slide 181 49 
 
49 49 
Total cells delivered 
  
3709 
 
EXP0218 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 15 
 
14 280 
Slide 21 13 
 
13 260 
Slide 41 13 
 
17 340 
Slide 61 21 
 
27 486 
Slide 81 33 
 
16.5 330 
Slide 101 0 
 
0 0 
Slide 121 0 
 
0 0 
Slide 141 0 
 
0 0 
Slide 161 0 
 
6.5 175.5 
Slide 188 13 
 
20.5 410 
Slide 208 28 
 
27.5 550 
Slide 228 27 
 
29.5 590 
Slide 248 32 
 
23 460 
Slide 268 14 
 
14 14 
Total cells delivered 
  
3895.5 
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EXP0219 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 14 
 
13.5 270 
Slide 21 13 
 
10.5 210 
Slide 41 8 
 
10 200 
Slide 61 12 
 
14.5 290 
Slide 81 17 
 
10 200 
Slide 101 3 
 
2.5 50 
Slide 121 2 
 
1.5 30 
Slide 141 1 
 
5.5 110 
Slide 161 10 
 
11 220 
Slide 181 12 
 
14.5 290 
Slide 201 17 
 
15.5 310 
Slide 221 14 
 
42 840 
Slide 241 70 
 
61 1220 
Slide 261 52 
 
43.5 870 
Slide 281 35 
 
20.5 410 
Slide 301 6 
 
6 6 
Total cells delivered 
  
5526 
 
EXP0220 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 3 
 
2 40 
Slide 21 1 
 
1.5 30 
Slide 41 2 
 
1 20 
Slide 61 0 
 
7 140 
Slide 81 14 
 
10.5 210 
Slide 101 7 
 
4 80 
Slide 121 1 
 
3 60 
Slide 141 5 
 
5 100 
Slide 161 5 
 
3.5 70 
Slide 181 2 
 
2 2 
Total cells delivered 
  
752 
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EXP0221 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 16 
 
15 300 
Slide 21 14 
 
24.5 490 
Slide 41 35 
 
29.5 590 
Slide 61 24 
 
20 400 
Slide 81 16 
 
20.5 410 
Slide 101 25 
 
18.5 370 
Slide 121 12 
 
10.5 210 
Slide 141 9 
 
9 9 
Total cells delivered 
  
2779 
 
EXP0224 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 1 
 
0.5 10 
Slide 21 0 
 
3 60 
Slide 41 6 
 
5.5 110 
Slide 61 5 
 
4 80 
Slide 81 3 
 
3.5 70 
Slide 101 4 
 
4 80 
Slide 121 4 
 
2 40 
Slide 141 0 
 
0.5 10 
Slide 161 1 
 
1 1 
Total cells delivered 
  
461 
 
EXP0225 
Counted 
hMSCs 
 
Average of 2 adjacent 
counted slides 
Average * # Slides 
Inbetween  
Slide 1 5 
 
8 160 
Slide 21 11 
 
10.5 210 
Slide 41 10 
 
10.5 210 
Slide 61 11 
 
11 11 
Total cells delivered 
  
591 
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Appendix C: Microthread Implantation Tracking Measurements 
 
Exp 214 
Slide 
Number 
Endocardia
l distance 
(mm) 
Epicardial 
distance 
(mm) 
Left ventricular wall 
thickness (mm) 
Endo distance/wall 
thickness (%) 
Epi 
distance/wall 
thickness (%) 
Slide 241 2.03 0 2.03 100 0 
Slide 221 1.096 1.744 2.84 38.6 61.4 
Slide 201 0.457 2.342 2.799 16.3 83.7 
Slide 181 0 3.09 3.09 0 100 
Slide 161 0 3.09 3.09 0 100 
Slide 141 0 3.09 3.09 0 100 
Slide 121 0 4.715 4.715 0 100 
Slide 101 0 4.33 4.33 0 100 
Slide 81 0 4.248 4.248 0 100 
Slide 61 0 4.017 4.017 0 100 
Slide 41 0 4.343 4.343 0 100 
Slide 21 0.249 3.432 3.681 6.8 93.2 
Slide 1 4.149 0 4.149 100 0 
 
Exp 215 
Slide 
Number 
Endocardia
l distance 
(mm) 
Epicardial 
distance 
(mm) 
Left ventricular wall 
thickness (mm) 
Endo distance/wall 
thickness (%) 
Epi 
distance/wall 
thickness (%) 
Slide 1 4.95 0 4.95 100 0 
Slide 21 4.136 0.78 4.916 84.1 15.9 
Slide 40 2.71 1.135 3.845 70.5 29.5 
Slide 61 1.49 1.98 3.47 42.9 57.1 
Slide 81 0.82 2.82 3.64 22.5 77.5 
Slide 103 1.2 2.76 3.96 30.3 69.7 
Slide 123 1.24 2.73 3.97 31.2 68.8 
Slide 143 0.96 1.95 2.91 33.0 67.0 
Slide 163 1.39 1.47 2.86 48.6 51.4 
Slide 183 2.77 0 2.77 100 0 
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Exp 217 
Slide 
Number 
Endocardia
l distance 
(mm) 
Epicardial 
distance 
(mm) 
Left ventricular wall 
thickness (mm) 
Endo distance/wall 
thickness (%) 
Epi 
distance/wall 
thickness (%) 
Slide 201 1.556 0 1.556 100 0 
Slide 181 1.305 1.7 3.005 43.4 56.6 
Slide 161 1.337 1.8711 3.2081 41.7 58.3 
Slide 141 1.8 2.33 4.13 43.6 56.4 
Slide 121 1.33 1.67 3 55.7 44.3 
Slide 101 0 2.62 2.62 0 100 
Slide 81 0.559 2.796 3.355 16.7 83.3 
Slide 61 0.577 2.436 3.013 19.2 80.8 
Slide 41 1.36 1.79 3.15 43.2 56.8 
Slide 21 2.23 0.88 3.11 71.7 28.3 
Slide 1 2.601 0 2.601 100 0 
 
Exp 218 
Slide 
Number 
Endocardia
l distance 
(mm) 
Epicardial 
distance 
(mm) 
Left ventricular wall 
thickness (mm) 
Endo distance/wall 
thickness (%) 
Epi 
distance/wall 
thickness (%) 
Slide 268 1.61 0 1.61 100 0 
Slide 248 0.2381 2.789 3.0271 7.9 92.1 
Slide 228 0 3.268 3.268 0 100 
Slide 208 0 3.296 3.296 0 100 
Slide 188 0 4.147 4.147 0 100 
Slide 161 0 3.34 3.34 0 100 
Slide 141 No Thread No Thread 3.629 0 100 
Slide 121 No Thread No Thread 3.66 0 100 
Slide 101 No Thread No Thread 3.66 0 100 
Slide 81 No Thread No Thread 2.156 0 100 
Slide 61 0 3.786 3.786 0 100 
Slide 41 0.664 3.1 3.764 17.6 82.4 
Slide 21 2.713 1.477 4.19 64.7 35.3 
Slide 1 2.581 0 2.581 100 0 
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Exp 219 
Slide 
Number 
Endocardia
l distance 
(mm) 
Epicardial 
distance 
(mm) 
Left ventricular wall 
thickness (mm) 
Endo distance/wall 
thickness (%) 
Epi 
distance/wall 
thickness (%) 
Slide 301 4.84 0 4.84 100 0 
Slide 281 3.11 1.27 4.38 71.1 28.9 
Slide 261 3.673 1.677 5.35 68.7 31.3 
Slide 241 3.077 2.341 5.418 56.8 43.2 
Slide 221 2.307 2.09 4.397 52.5 47.5 
Slide 201 1.321 1.198 2.519 52.4 47.6 
Slide 181 0.821 0.886 1.707 48.1 51.9 
Slide 161 0.89 1.175 2.065 43.1 56.9 
Slide 141 1.1 1.73 2.83 38.9 61.1 
Slide 121 1.47 2.25 3.72 39.5 60.5 
Slide 101 1.09 2.41 3.5 31.1 68.9 
Slide 81 0.93 3.01 3.94 23.6 76.4 
Slide 61 1.28 2.46 3.74 34.2 65.8 
Slide 41 3.64 0.594 4.234 86.0 14.0 
Slide 21 3.74 0.41 4.15 90.1 9.9 
Slide 1 3.89 0 3.89 100 0 
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Appendix D: Surgical Notes 
Experiment number EXP0214 
Experiment date 09/09/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 690 grams 
Drugs administered (volume) Ketamine (1.04 mL), Xylazine (0.05 mL), Isoflurane (2% 
vaporized) 
Implantation type 8 fibrin, 4 collagen microthread bundle seeded with 
hMSCs 
hMSC passage number Passage 7 
Target survival time 1 hour 
Time anesthetized  9:25 am 
Time intubated, isoflurane administered 9:50 am 
First incision 10:02 am 
Microthread implantation time 10:21 am 
Euthanasia time 11:27 am 
Rat heart rate and Sp02 prior to 
euthanasia 
Equipment not available 
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Experiment number EXP0215 
Experiment date 09/16/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 442 grams 
Drugs administered (volume) Ketamine (0.64 mL), Xylazine (0.03 mL), Isoflurane (2% 
vaporized) 
Implantation type 8 fibrin, 4 collagen microthread bundle seeded with 
hMSCs 
hMSC passage number Passage 8 
Target survival time 1 hour 
Time anesthetized  9:05 am 
Time intubated, isoflurane administered 9:15 am 
First incision 9:30 am 
Microthread implantation time 9:48 am 
Euthanasia time 10:58 am 
Rat heart rate and Sp02 prior to 
euthanasia 
Equipment not available 
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Experiment number EXP0217 
Experiment date 10/07/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 540 grams 
Drugs administered (volume) Ketamine (0.57 mL), Xylazine (0.03 mL), Isoflurane (2% 
vaporized) 
Implantation type 8 fibrin, 4 collagen microthread bundle seeded with 
hMSCs 
hMSC passage number Passage 9 
Target survival time 1 hour 
Time anesthetized  8:39 am 
Time intubated, isoflurane administered 9:12 am 
First incision 9:28 am 
Microthread implantation time 9:38 am 
Euthanasia time 10:45 am 
Rat heart rate and Sp02 prior to 
euthanasia 
224 beats per minute, 99% Sp02 
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Experiment number EXP0218 
Experiment date 10/21/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 593 grams 
Drugs administered (volume) Ketamine (0.75 mL), Xylazine (0.04 mL), Isoflurane (2% 
vaporized) 
Implantation type 8 fibrin, 4 collagen microthread bundle seeded with 
hMSCs 
hMSC passage number Passage 9 
Target survival time 1 hour 
Time anesthetized  8:40 am 
Time intubated, isoflurane administered 9:20 am 
First incision 9:25 am 
Microthread implantation time 9:45 am 
Euthanasia time 10:45 am 
Rat heart rate and Sp02 prior to 
euthanasia 
227 beats per minute, 94% Sp02 
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Experiment number EXP0219 
Experiment date 10/21/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 616 grams 
Drugs administered (volume) Ketamine (0.68 mL), Xylazine (0.04 mL), Isoflurane (2% 
vaporized) 
Implantation type 8 fibrin, 4 collagen microthread bundle seeded with 
hMSCs 
hMSC passage number Passage 9 
Target survival time 1 hour 
Time anesthetized  10:40 am 
Time intubated, isoflurane administered 10:50 am 
First incision 11:07 am 
Microthread implantation time 11:20 am 
Euthanasia time 12:20 am 
Rat heart rate and Sp02 prior to 
euthanasia 
210 beats per minute, 96% Sp02 
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Experiment number EXP0220 
Experiment date 10/28/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 655 grams 
Drugs administered (volume) Ketamine (0.67 mL), Xylazine (0.04 mL), Isoflurane (2% 
vaporized) 
Implantation type Intramyocardial injection of hMSCs 
hMSC passage number Passage 9 
Target survival time 1 hour 
Time anesthetized  8:45 am 
Time intubated, isoflurane administered 9:25 am 
First incision 9:33 am 
hMSC injection time 10:22 am 
Euthanasia time 11:25 am 
Rat heart rate and Sp02 prior to 
euthanasia 
182 beats per minute, 92% Sp02 
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Experiment number EXP0221 
Experiment date 11/02/2009 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 462 grams 
Drugs administered (volume) Ketamine (0.68 mL), Xylazine (0.05 mL), Isoflurane (2% 
vaporized) 
Implantation type Intramyocardial injection of hMSCs 
hMSC passage number Passage 6 
Target survival time 1 hour 
Time anesthetized  8:40 am 
Time intubated, isoflurane administered 9:10 am 
First incision 9:32 am 
hMSC injection time 9:51 am 
Euthanasia time 11:00 am 
Rat heart rate and Sp02 prior to 
euthanasia 
227 beats per minute, 96% Sp02 
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Experiment number EXP0224 
Experiment date 01/06/2010 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 572 grams 
Drugs administered (volume) Ketamine (1.36 mL), Xylazine (0.13 mL), Isoflurane (2% 
vaporized) 
Implantation type Intramyocardial injection of hMSCs 
hMSC passage number Passage 7 
Target survival time 1 hour 
Time anesthetized  9:40 am 
Time intubated, isoflurane administered 9:46 am 
First incision 10:00 am 
hMSC injection time 10:32 am 
Euthanasia time 11:35 am 
Rat heart rate and Sp02 prior to 
euthanasia 
205 beats per minute, 91% Sp02 
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Experiment number EXP0225 
Experiment date 01/13/2010 
Rat sex Male 
Rat type Sprague Dawley 
Rat weight 588 grams 
Drugs administered (volume) Ketamine (0.61 mL), Xylazine (0.03 mL), Isoflurane (2% 
vaporized) 
Implantation type Intramyocardial injection of hMSCs 
hMSC passage number Passage 8 
Target survival time 1 hour 
Time anesthetized  8:40 am 
Time intubated, isoflurane administered 9:15 am 
First incision 10:10 am 
hMSC injection time 10:35 am 
Euthanasia time 11:27 am 
Rat heart rate and Sp02 prior to 
euthanasia 
170 beats per minute, 96% Sp02 
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Appendix E: Surgical Procedure 
 
Materials: 70% ethanol, betadine solution, saline solution, sterile q-tips, sterile gauze, non-sterile gauze, 
sterile surgical drape, sterile no. 10 scalpel blade, 6-0 Prolene suture, rat intubation kit, non-sterile gauze, 
16 gauge catheter, catheter guide, (3) sterile 1 cc syringes, surgical stapler, (3) 27 gauge syringe needles, 
proper sized sterile surgeon’s gloves, non-sterile drapes, (2) towel clamps, sterile scalpel, Hamilton 100 
µL glass syringe, protective rat handling glove, surgical scissors, iris scissors, rib spreader, plastic tub, 
forceps, cauterizer with sterile head, needle holders (large and small), Xylazine, Isoflurane, Ketamine, 
Lidocaine, Pentobarbital, Plexiglass rat intubation container, ventilator, tubing to connect ventilator to 
isoflurane dispenser to the rat, isoflurane dispenser, digital scale, electric shaver, surgical tape, suture 
needle with quantum dot loaded hMSC seeded fibrin thread attached, pulse oximeter 
Procedure: 
1. Put plastic tub on digital scale and re-calibrate 
2. Grab the base of the rat’s tail and put on scale 
3. Record weight and return rat to cage 
4. Calculate the necessary concentrations of Xylazine and Ketamine to sedate the rat 
a. Drug concentration of Ketamine: 100 mg/kg 
b. Drug concentration of Xylazine: 10 mg/kg 
5. Use a 1 cc syringe with a 27 gauge needle to inject the calculated drug concentrations into the rat 
6. Put rat back in cage for 5 minutes or until completely sedated  
a. Check if rat is completely sedated by gently touching the eye and looking for the rat to 
flinch 
b. If rat does not become completely sedated inject an additional 10% (of the initial 
calculated concentration) of both drugs into the rat and wait 5 minutes after each injection 
to test sedation 
7. Put the rat on non-sterile drapes and position the rat so that the left side is facing up, allowing 
access to the abdominal region 
8. Shave all fur between the front and hind legs  
9. Put rat on top of the intubation container and intubate 
10. Ensure intubation by putting a mirror in front of the catheter and checking for condensation 
11. Gently move rat onto new non-sterile drapes (left side facing up) 
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12. Use surgical tape to tape one front and hind leg (the ones closest to the drapes) to the drapes on 
the table 
13. Connect to ventilator tubing to the 16 gauge catheter that was intubated earlier 
14. Use the isoflurane dispenser to add 2.0% isoflurane to the air reaching the rat 
15. Ensure ventilator function by checking chest for expansion and contraction in correlation with 
ventilator 
16. Rinse shaved area with betadine and 70% ethanol 3x with non-sterile gauze (rinse with betadine 
first) 
17. Put on sterile surgical gloves 
18. Put sterile drapes over the rat and cut a hole with blunt-end surgical scissors over the area of 
incision 
19. Use scalpel, iris scissors, and cauterizer to gain access to abdominal cavity, making sure not to 
puncture any organs or vessels 
20. Use towel clamps to clamp the outside area of incision (skin) to the sterile drapes  
21. Use rib spreaders to improve access to the heart 
22. Pass suture needle with quantum dot loaded hMSC seeded biological microthreads through left 
ventricular wall and cut the biological microthread end attached to the needle as soon as it 
appears OR inject 35 µL of hMSC suspension (10,000 cells) into the left ventricular wall 
23. Wait 1 hour, making sure to monitor vital signs (heart rate Sp02 
24. Euthanize the animal with pentobarbital  
25. Remove the heart for histological analysis 
26. Rinse heart 3x with PBS 
27. Place heart in 4% paraformaldehyde at 4⁰C 
 
 
